Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUSRE42208 E1
Publication typeGrant
Application numberUS 12/147,042
Publication dateMar 8, 2011
Filing dateJun 26, 2008
Priority dateApr 29, 2003
Also published asCA2522133A1, CA2522133C, CA2563082A1, CA2563082C, DE602004015093D1, EP1618178A2, EP1618178A4, EP1618178B1, EP1740121A2, EP1740121A4, US7067123, US20040219182, US20060210643, US20080133008, US20110196508, US20140058527, WO2004096983A2, WO2004096983A3, WO2005110278A2, WO2005110278A3
Publication number12147042, 147042, US RE42208 E1, US RE42208E1, US-E1-RE42208, USRE42208 E1, USRE42208E1
InventorsKatherine Gomes Truncale, Arthur A. Gertzman, Moon Hae Sunwoo, William W. Tomford
Original AssigneeMusculoskeletal Transplant Foundation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Glue for cartilage repair
US RE42208 E1
Abstract
The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers with allogenic chondrocytes or bone marrow cells in an amount exceeding the natural occurrence of same in hyaline cartilage and adding a cell growth additive.
Images(2)
Previous page
Next page
Claims(83)
1. A sterile allograft cartilage defect implant repair material for use in human beings, comprising a mixture including lyophilized, freeze-milled allograft cartilage pieces sized less having a size not greater than 1 mm and a bioabsorbable carrier, said cartilage pieces being formed from allograft cartilage that has been lyophilized so that their as to reduce its water content ranges from to an amount within the range of from about 0.1% to about 8.0% in a bioabsorbable carrier by weight.
2. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.
3. A sterile allograft cartilage defect implant material as claimed in claim 1 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.
4. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said bioabsorbable carrier is selected from the group consisting of sodium hyaluronate and its derivatives hyaluronic acid.
5. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said implant material mixture includes a protein glue.
6. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said implant material mixture includes the addition of autologous chondrocytes to achieve a concentration exceeding the concentration of chondrocytes naturally occurring in the patient at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years to 55 years.
7. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is pieces include hyaline cartilage.
8. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is fibrosus cartilage pieces include fibrocartilage.
9. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said milled allograft cartilage is pieces include hyaline and fibrosus cartilage fibrocartilage.
10. A sterile allograft cartilage defect implant repair material as claimed in claim 1, including wherein said mixture includes an additive to said implant material consisting of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, a human demineralized bone matrix, and insulin, insulin-like growth factor- 1, an interleukin- 1, receptor agonist, a hepatocyte growth factor, a platelet-derived growth factor, Indian hedgehog, and a parathryroid hormone-related peptide.
11. A sterile cartilage defect repair material as claimed in claim 10, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.
12. A sterile allograft cartilage defect implant repair material as claimed in claim 1, wherein said bioabsorbable carrier comprises one or more bioabsorbable carriers taken is selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives , gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or and polymers.
13. A sterile allograft cartilage defect implant repair material for use in human beings, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in , a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or and polymers, and allogenic chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years.
14. A sterile cartilage defect implant repair material as claimed in claim 13, wherein said allograft articular cartilage is pieces include hyaline cartilage.
15. A sterile allograft cartilage defect implant repair material as claimed in claim 13, wherein said milled allograft articular cartilage is fibrous cartilage pieces include fibrocartilage.
16. A sterile allograft cartilage defect implant repair material as claimed in claim 13, wherein said milled allograft articular cartilage is pieces include hyaline cartilage and fibrous cartilage fibrocartilage.
17. A sterile cartilage defect repair material as claimed in claim 13 wherein said implant material includes , further comprising an additive consisting of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, human allogenic bone marrow cells, human autologous bone marrow cells, human allogenic stem cells, human autologous stem cells, demineralized bone matrix, and insulin, insulin-like growth factor- 1, interleukin- 1 receptor agonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog, and parathyroid hormone-related peptide.
18. A sterile cartilage defect repair material as claimed in claim 17, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.
19. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 25% to about 50% by weight and said carrier ranges from about 75% to about 50% by weight.
20. A sterile cartilage defect implant material as claimed in claim 13 wherein said milled cartilage ranges from about 15% to about 30% by weight with the carrier ranging from about 85% to about 70% by weight.
21. A sterile allograft cartilage defect implant repair material for use in human beings, comprising lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in , a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives , gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or , and polymers, and autologous bone marrow cells in an amount exceeding the natural occurrence of same in a patient being treated at a concentration greater than the concentration of bone marrow cells that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years to 55 years.
22. A sterile cartilage defect repair material as claimed in claim 21 including , further comprising an additive in said implant material which consists of one or more of a selected from the group consisting of a growth factors factor, human allogenic cells, autologous chondrocytes, demineralized bone matrix, and insulin, insulin-like growth factor- 1, an interleukin- 1 receptor agonist, a hepatocyte growth factor, a platelet-derived growth factor, Indian hedgehog, and a parathyroid hormone-related peptide.
23. A sterile cartilage defect repair material as claimed in claim 22, wherein said growth factors are one or more of a factor is selected from the group consisting of FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, and VEGF.
24. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said bioabsorbable carrier consists is selected from the group consisting of sodium hyaluronate, and hyaluronic acid and its derivatives .
25. A sterile cartilage defect repair material as claimed in claim 21; wherein said lyophilized allograft articular cartilage pieces have ranging from are formed from allograft articular cartilage that has been lyophilized so as to reduce its water content to the range of about 0.1% to about 8.0%.
26. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said allograft articular cartilage is pieces include hyaline cartilage.
27. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage is fibrous cartilage pieces include fibrocartilage.
28. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage is pieces include hyaline cartilage and fibrous cartilage fibrocartilage.
29. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage ranges pieces are present in said material at an amount in the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said material at an amount in the range of from about 75% 50% to about 50% 75% by weight.
30. A sterile allograft cartilage defect implant repair material as claimed in claim 21, wherein said milled allograft articular cartilage ranges pieces are present in said material in an amount in the range of from about 15% to about 30% by weight with the and said bioabsorbable carrier ranging is present in said material in an amount in the range of from about 85% 70% to about 70% 85% by weight.
31. A sterile cartilage defect implant material comprising lyophilized milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran or polymers and autologous stem cells in an amount exceeding the natural occurrence of same in a patient being treated.
32. A method of placing a cartilage defect repair material in a cartilage defect site in a human being, said the cartilage defect repair material comprising having a mixture including lyophilized freeze-milled allograft articular cartilage which has been lyophilized and mixed in pieces and a bioabsorbable carrier, said method comprising the steps of:
(a) cutting a patient's tissue at a site of a cartilage defect to remove a diseased area of cartilage from the cartilage defect site;
(b) adding autologous cells to said the mixture of milled allograft cartilage in a bioabsorbable carrier ;
(c) placing a the mixture of milled allograft cartilage with the added autologous cells in a bioabsorbable carrier in into the cartilage defect area where cartilage has been removed site; and
(d) placing a cover over the mixture of milled allograft cartilage in a bioabsorbable carrier and the added cells so as to contain the mixture and the added cells in the cartilage defect site for a predetermined period of time .
33. The method of claim 32, wherein further comprising the step of adding growth factors are added to said the mixture.
34. The method of claim 32, wherein said autologous cells are include chondrocytes.
35. The method of claim 32, wherein said autologous cells are include bone marrow cells.
36. The method of claim 32, wherein said autologous cells are include stem cells.
37. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in , a bioabsorbable carrier taken selected from a the group consisting of sodium hyaluronate, hyaluronic acid and its derivatives , and chitosan, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.
38. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in , a bioabsorbable carrier taken selected from a the group consisting of gelatin, collagen, and alginate, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.
39. A sterile allograft cartilage defect implant repair material for use in a human being, comprising a mixture including lyophilized, freeze-milled allograft articular cartilage pieces ranging from 0.01 mm to 1.0 mm in size in , a bioabsorbable carrier taken selected from a the group consisting of buffered PBS, Dextran or , and polymers, and autologous chondrocytes in an amount exceeding the natural occurrence of same in articular cartilage at a concentration greater than the concentration of chondrocytes that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years, wherein said milled allograft articular cartilage ranges pieces are present in said mixture at an amount within the range of from about 25% to about 50% by weight and said bioabsorbable carrier ranges is present in said mixture at an amount within the range of from about 75% 50% to about 50% 75% by weight.
40. A cartilage defect repair material as claimed in claim 1, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 25% to about 50 % by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 50 % to about 75 % by weight.
41. A cartilage defect repair material as claimed in claim 1, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 15% to about 30 % by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 70 % to about 85 % by weight.
42. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized. freeze-milled allograft cartilage pieces lack cell viability.
43. A cartilage defect repair material as claimed in claim 1, wherein said cartilage defect repair material is free of bone pieces.
44. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces are formed by a process including the steps of harvesting a donor tissue consisting essentially of articular cartilage, lyophilizing said donor tissue, and freeze-milling said donor tissue.
45. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces are formed by milling frozen allograft articular cartilage.
46. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
47. A cartilage defect repair material as claimed in claim 1, wherein said cartilage defect repair material is free of added chondrocytes.
48. A cartilage defect repair material as claimed in claim 1, wherein said lyophilized, freeze-milled allograft cartilage pieces have an ability to promote the growth of new articular cartilage in the cartilage defect.
49. A cartilage defect repair material as claimed in claim 13, wherein said mixture includes a protein glue.
50. A cartilage defect repair material as claimed in claim 13, wherein said allograft articular cartilage pieces are formed from allograft articular cartilage that has been lyophilized so as to reduce its water content to the range of from about 0.1% to about 8.0 % by weight.
51. A cartilage defect repair material as claimed in claim 13, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 25% to about 50 % by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 50 % to about 75 % by weight.
52. A cartilage defect repair material as claimed in claim 13, wherein said cartilage pieces are present in said mixture at an amount within the range of from about 15% to about 30 % by weight, and said bioabsorbable carrier is present in said mixture at an amount within the range of from about 70 % to about 85 % by weight.
53. A cartilage defect repair material as claimed in claim 21, further comprising a protein glue.
54. The method of claim 32, further comprising the step of fixing the mixture in the cartilage defect site with an organic glue.
55. The method of claim 32, further comprising the step of keeping the cover over the mixture for a predetermined period of time that is sufficient to promote cartilage growth at the cartilage defect site.
56. The method of claim 32, wherein said cover is a periosteal flap.
57. The method of claim 32, wherein said cover is a perichondrial flap.
58. The method of claim 32, wherein, in said step (b), the cells are selected from the group consisting of chondrocytes, bone marrow cells and stem cells, and the cells are added so as to achieve a concentration greater than the concentration of corresponding cells that are naturally present in hyaline cartilage of a human being having an age in the range of from 20 years and 55 years.
59. A cartilage defect repair material for use in human beings, comprising lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm, wherein said cartilage pieces are included in a mixture that also includes a bioabsorbable carrier, said cartilage pieces being present in said mixture at an amount within the range of from about 25 % to about 50 % by weight, and said bioabsorbable carrier being present in said mixture at an amount within the range of from about 50 % to about 75 % by weight.
60. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0 % by weight.
61. A cartilage defect repair material as claimed in claim 59, wherein said size ranges from 0.01 mm to 1.0 mm.
62. A cartilage defect repair material as claimed in claim 59, wherein said material is free of added chondrocytes.
63. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
64. A cartilage defect repair material as claimed in claim 59, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization.
65. A cartilage defect repair material for use in human beings, comprising lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm, wherein said cartilage pieces are included in a mixture that also includes a bioabsorbable carrier, said cartilage pieces being present in said mixture at an amount within the range of from about 15 % to about 30 % by weight, and said bioabsorbable carrier being present in said mixture at an amount within the range of from about 70 % to about 85 % by weight.
66. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed from allograft cartilage that has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0 % by weight.
67. A cartilage defect repair material as claimed in claim 65, wherein said size ranges from 0.01 mm to 1.0 mm.
68. A cartilage defect repair material as claimed in claim 65, wherein said material is free of added chondrocytes.
69. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
70. A cartilage defect repair material as claimed in claim 65, wherein said cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization.
71. A method of repairing a cartilage defect in a human being, comprising the step of placing in a defect site lyophilized, freeze-milled allograft cartilage pieces having a size not greater than 1 mm.
72. A method as claimed in claim 71, wherein the cartilage pieces have a water content ranging from about 0.1% to about 8.0 % by weight prior to their placement in the defect site.
73. A method as claimed in claim 71, wherein the cartilage pieces are formed from allograft cartilage which has been lyophilized so as to reduce its water content to an amount within the range of from about 0.1% to about 8.0 % by weight.
74. A method as claimed in claim 71, wherein the size ranges from 0.01 mm to 1.0 mm.
75. A method as claimed in claim 71, wherein the cartilage pieces are formed by freezing allograft cartilage with liquid nitrogen and milling the frozen cartilage.
76. A method as claimed in claim 71, wherein the cartilage pieces are formed by freeze-milling allograft cartilage subsequent to lyophilization of the allograft cartilage.
77. A method as claimed in claim 71, wherein the defect site includes a defect in articular cartilage.
78. A method as claimed in claim 77, wherein the cartilage pieces have an ability to promote the growth of new articular cartilage in the articular cartilage defect.
79. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces consist essentially of articular cartilage.
80. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces lack cell viability.
81. A method as claimed in claim 71, comprising the further steps of harvesting a donor tissue consisting essentially of articular cartilage, lyophilizing said donor tissue, and freeze-milling said donor tissue.
82. A method as claimed in claim 71, comprising the further step of forming the lyophilized, freeze-milled allograft cartilage pieces by a process including the step of milling frozen allograft articular cartilage.
83. A method as claimed in claim 71, wherein the lyophilized, freeze-milled allograft cartilage pieces are free of added chondrocytes.
Description
RELATED APPLICATIONS

There is no related application.The instant application is a reissue of application Ser. No. 10/424,765, filed Apr. 29, 2003, and issued as U.S. Pat. No. 7,067,123.

1. Field of Invention

The present invention is generally directed toward an implant and is more specifically directed toward a paste or gel implant material for a cartilage defect.

2. Background of the Invention

Articular cartilage injury and degeneration present medical problems to the general population which are addressed by orthopedic surgeons. Every year in the United States, over 500,000 arthroplastic or joint repair procedures are performed. These include approximately 125,000 total hip and 150,000 total knee arthroplasties and over 41,000 open arthroscopic procedures to repair cartilaginous defects of the knee.

In the knee joint, the articular cartilage tissue forms a lining which faces the joint cavity on one side and is linked to the subchondral bone plate by a narrow layer of calcified cartilage tissue on the other. Articular cartilage (hyaline cartilage) consists primarily of extracellular matrix with a sparse population of chondrocytes distributed throughout the tissue. Articular cartilage is composed of chondrocytes, type II collagen fibril network, proteoglycans and water. Active chondrocytes are unique in that they have a relatively low turnover rate and are sparsely distributed within the surrounding matrix. The collagens give the tissue its form and tensile strength and the interaction of proteoglycans with water give the tissue its stiffniess to compression, resilience and durability. The hyaline cartilage provides a low friction bearing surface over the bony parts of the joint. If the lining becomes worn or damaged resulting in lesions, joint movement may be painful or severely restricted. Whereas damaged bone typically can regenerate successfully, hyaline cartilage regeneration is quite limited because of it's limited regenerative and reparative abilities.

Articular cartilage lesions generally do not heal, or heal only partially under certain biological conditions due to the lack of nerves, blood vessels and a lymphatic system. The limited reparative capabilities of hyaline cartilage usually results in the generation of repair tissue that lacks the structure and biomechanical properties of normal cartilage. Generally, the healing of the defect results in a fibrocartilaginous repair tissue that lacks the structure and biomedical properties of hyaline cartilage and degrades over the course of time. Articular cartilage lesions are frequently associated with disability and with symptoms such as joint pain, locking phenomena and reduced or disturbed function. These lesions are difficult to treat because of the distinctive structure and function of hyaline cartilage. Such lesions are believed to progress to severe forms of osteoarthritis. Osteoarthritis is the leading cause of disability and impairment in middle-aged and older individuals, entailing significant economic, social and psychological costs. Each year, osteoarthritis accounts for as many as 39 million physician visits and more than 500,000 hospitalizations. By the year 2020, arthritis is expected to affect almost 60 million persons in the United States and to limit the activity of 11.6 million persons.

There are many current therapeutic methods being used. None of these therapies has resulted in the successful regeneration of hyaline-like tissue that withstands normal joint loading and activity over prolonged periods. Currently, the techniques most widely utilized clinically for cartilage defects and degeneration are not articular cartilage substitution procedures, but rather lavage, arthroscopic debridement, and repair stimulation. The direct transplantation of cells or tissue into a defect and the replacement of the defect with biologic or synthetic substitutions presently accounts for only a small percentage of surgical interventions. The optimum surgical goal is to replace the defects with cartilage-like substitutes so as to provide pain relief, reduce effusions and inflammation, restore function, reduce disability and postpone or alleviate the need for prosthetic replacement.

Lavage and arthroscopic debridement involve irrigation of the joint with solutions of sodium chloride, Ringer or Ringer and lactate. The temporary pain relief is believed to result from removing degenerative cartilage debris, proteolytic enzymes and inflammatory mediators. These techniques provide temporary pain relief, but have little or no potential for further healing.

Repair stimulation is conducted by means of drilling, abrasion arthroplasty or microfracture. Penetration into the subchondral bone induces bleeding and fibrin clot formation which promotes initial repair, however, the tissue formed is fibrous in nature and not durable. Pain relief is temporary as the tissue exhibits degeneration, loss of resilience, stiffness and wear characteristics over time.

The periosteum and perichondrium have been shown to contain mesenchymal progenitor cells capable of differentiation and proliferation. They have been used as grafts in both animal and human models to repair articular defects. Few patients over 40 years of age have obtained good clinical results, which most likely reflects the decreasing population of osteochondral progenitor cells with increasing age. There have also been problems with adhesion and stability of the grafts, which result in their displacement or loss from the repair site.

Transplantation of cells grown in culture provides another method of introducing a new cell population into chondral and osteochondral defects. Carticel® is a commercial process to culture a patient's own cartilage cells for use in the repair of cartilage defects in the femoral condyle marketed by Genzyme Biosurgery in the United States and Europe. The procedure uses arthroscopy to take a biopsy from a healthy, less loaded area of articular cartilage. Enzymatic digestion of the harvested tissue releases the cells that are sent to a laboratory where they are grown for a period ranging from 2-5 weeks. Once cultivated, the cells are injected during a more open and extensive knee procedure into areas of defective cartilage where it is hoped that they will facilitate the repair of damaged tissue. An autologous periosteal flap with cambium layer is used to seal the transplanted cells in place and act as a mechanical barrier. Fibrin glue is used to seal the edges of the flap. This technique preserves the subchondral bone plate and has reported a high success rate. Proponents of this procedure report that it produces satisfactory results, including the ability to return to demanding physical activities, in more than 90% of patients and that biopsy specimens of the tissue in the graft sites show hyaline-like cartilage repair. More work is needed to assess the function and durability of the new tissue and determine whether it improves joint function and delays or prevents joint degeneration. As with the perichondrial graft, patient/donor age may compromise the success of this procedure as chondrocyte population decreases with increasing age. Disadvantages to this procedure include the need for two separate surgical procedures, potential damage to surrounding cartilage when the periosteal patch is sutured in place, the requirement of demanding microsurgical techniques, and the expensive cost of the procedure which is currently not covered by insurance.

Osteochondral transplantation or mosaicplasty involves excising all injured or unstable tissue from the articular defect and creating cylindrical holes in the base of the defect and underlying bone. These holes are filled with autologous cylindrical plugs of healthy cartilage and bone in a mosaic fashion. The osteochondral plugs are harvested from a lower weight-bearing area of lesser importance in the same joint. This technique, shown in Prior Art FIG. 2, can be performed as arthroscopic or open procedures. Reports of results of osteochondral plug autografts in a small number of patients indicate that they decrease pain and improve joint function, however, long-term results have not been reported. Factors that can compromise the results include donor site morbidity, effects of joint incongruity on the opposing surface of the donor site, damage to the chondrocytes at the articular margins of the donor and recipient sites during preparation and implantation, and collapse or settling of the graft over time. The limited availability of sites for harvest of osteochondral autografts restricts the use of this approach to treatment of relatively small articular defects and the healing of the chondral portion of the autograft to the adjacent articular cartilage remains a concern.

Transplantation of large allografts of bone and overlying articular cartilage is another treatment option that involves a greater area than is suitable for autologous cylindrical plugs, as well as for a non-contained defect. The advantages of osteochondral allografts are the potential to restore the anatomic contour of the joint, lack of morbidity related to graft harvesting, greater availability than autografts and the ability to prepare allografts in any size to reconstruct large defects. Clinical experience with fresh and frozen osteochondral allografts shows that these grafts can decrease joint pain, and that the osseous portion of an allograft can heal to the host bone and the chondral portion can function as an articular surface. Drawbacks associated with this methodology in the clinical situation include the scarcity of fresh donor material and problems connected with the handling and storage of frozen tissue. Fresh allografts carry the risk of immune response or disease transmission. Musculoskeletal Transplant Foundation (MTF) has preserved fresh allografts in a media that maintains a cell viability of 50% for 35 days for use as implants. Frozen allografts lack cell viability and have shown a decreased amount of proteoglycan content which contribute to deterioration of the tissue.

A number of patents in the prior art show the use of bone putty, pastes or gels to fill bone defects. U.S. Pat. No. 5,290,558 issued Mar. 1, 1994 discloses a flowable demineralized bone powder composition using an osteogenic bone powder with large particle size ranging from about 0.1 to about 1.2 cm. mixed with a low molecular weight polyhydroxy compound possessing from 2 to about 18 carbons including a number of classes of different compounds such as monosaccharides, disaccharides, water dispersible oligosaccharides and polysaccharides.

A bone gel is disclosed in the U.S. Pat. No. 5,073,373 issued Dec. 17, 1991. Bone lamellae in the shape of threads or filaments retaining low molecular weight glycerol carrier are disclosed in U.S. Pat. Nos. 5,314,476 issued May 24, 1994 and 5,507,813 issued Apr. 16, 1996 and the tissue forms described in these patents are known commercially as the GRAFTON® Putty and Flex, respectively.

U.S. Pat. No. 5,356,629 issued Oct. 18, 1994 discloses making a rigid gel in the nature of a bone cement to fill defects in bone by mixing biocompatible particles, preferably polymethylmethacrylate coated with polyhydroxyethylmethacrylate in a matrix selected from a group which lists hyaluronic acid to obtain a molded semi-solid mass which can be suitably worked for implantation into bone. The hyaluronic acid can also be utilized in monomelic form or in polymeric form preferably having a molecular weight not greater than about one million Daltons. It is noted that the nonbioabsorbable material which can be used to form the biocompatible particles can be derived from xenograft bone, homologous bone, autogenous bone as well as other materials. The bioactive substance can also be an osteogenic agent such as demineralized bone powder, morselized cancellous bone, aspirated bone marrow and other autogenous bone sources. The average size of the particles employed is preferably about 0.1 to about 3.0 mm, more preferably about 0.2 to about 1.5 mm, and most preferably about 0.3 to about 1.0 mm. It is inferentially mentioned but not taught that particles having average sizes of about 7,000 to 8,000 microns, or even as small as about 100 to 700 microns can be used.

U.S. Pat. No. 4,172,128 issued Oct. 23, 1979 discloses a demineralized bone material mixed with a carrier to reconstruct tooth or bone material by adding a mucopolysaccharide to a mineralized bone colloidal material. The composition is formed from a demineralized coarsely ground bone material, which may be derived from human bones and teeth, dissolved in a solvent forming a colloidal solution to which is added a physiologically inert polyhydroxy compound such as mucopolysaccharide or polyuronic acid in an amount which causes orientation when hydrogen ions or polyvalent metal ions are added to form a gel. The gel will be flowable at elevated temperatures above 35° C. and will solidify when brought down to body temperature. Example 25 of the patent notes that mucopolysaccharides produce pronounced ionotropic effects and that hyaluronic acid is particularly responsible for spatial cross-linking.

U.S. Pat. No. 6,030,635 issued Feb. 29, 2000 and U.S. Pat. No. 6,437,018 issued Aug. 20, 2002 are directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which utilize a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier which contains a sodium phosphate saline buffer.

The use of implants for cartilage defects is much more limited. Aside from the fresh allograft implants and autologous implants, U.S. Pat. No. 6,110,209 issued Nov. 5, 1998 shows the use an autologous articular cartilage cancerous bone paste to fill arthritic defects. The surgical technique is arthroscopic and includes debriding (shaving away loose or fragmented articular cartilage), followed by morselizing the base of the arthritic defect with an awl until bleeding occurs. An osteochondral graft is then harvested from the inner rim of the intercondylar notch using a trephine. The graft is then morselized in a bone graft crusher, mixing the articular cartilage with the cancellous bone. The paste is then pushed into the defect and secured by the adhesive properties of the bleeding bone. The paste can also be mixed with a cartilage stimulating factor, a plurality of cells, or a biological glue. All patients are kept non-weight bearing for four weeks and used a continuous passive motion machine for six hours each night. Histologic appearance of the biopsies have mainly shown a mixture of fibrocartilage with hyaline cartilage. Concerns associated with this method are harvest site morbidity and availability, similar to the mosaicplasty method. cl SUMMARY OF THE INVENTION

A cartilage implant material in paste or gel form for repairing articular cartilage defects is composed of milled allograft cartilage pieces in a bioabsorbable carrier. Autologous chondrocyte in an amount exceeding the number naturally occurring in hyaline cartilage for a mature adult between 20 and 55 years of age may also be applied to the matrix. Additives may be applied to the mixture in order to increase chondrocyte migration and proliferation. The implant material can support the addition of a variety of chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic or autologous bone marrow cells, stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, transforming growth factor-B, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide or bioactive glue.

The implant material is placed in the lesion area and may be sealed with a periosteum cap.

It is an object of the invention to provide an allograft implant material for joints which provides pain relief, restores normal function and will postpone or alleviate the need for prosthetic replacement.

It is also an object of the invention to provide a cartilage repair implant material which is easily placed in a defect area by the surgeon using an arthroscopic, minimally invasive technique.

It is further an object of the invention to provide an allograft implant material procedure which is applicable for both partial and full thickness lesions.

It is yet another object of the invention to provide an allograft implant material which facilitates growth of hyaline cartilage.

It is an additional object of the invention to provide implant paste and gel material formulations that satisfy surgical requirements and are made from donated human available allograft tissue, some of which would otherwise be considered waste and thrown away.

These and other objects, advantages, and novel features of the present invention will become apparent when considered with the teachings contained in the detailed disclosure along with the accompanying drawings.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the anatomy of a knee joint with a lesion;

FIG. 2 shows a schematic mosaicplasty as known in the prior art; and

FIG. 3 shows a schematic perspective view of cartilage defect material placed in a defect site with an exploded periosteum cap.

DESCRIPTION OF THE INVENTION

The terms “tissue” is used in the general sense herein to mean any transplantable or implantable tissue, the survivability of which is improved by the methods described herein upon implantation. In particular, the overall durability and longevity of the implant are improved, and host-immune system mediated responses, are substantially eliminated.

The terms “transplant” and “implant” are used interchangably to refer to tissue, material or cells (xenogeneic or allogeneic) which may be introduced into the body of a patient to replace or supplement the structure or function of the endogenous tissue.

The terms “autologous” and “autograft” refer to tissue or cells which originate with or are derived from the recipient, whereas the terms “allogeneic” and “allograft” refer to cells and tissue which originate with or are derived from a donor of the same species as the recipient. The terms “xenogeneic” and “xenograft” refer to cells or tissue which originates with or is derived from a species other than that of the recipient.

The term “gel” refers to a mixture of minced or milled pretreated allograft cartilage in a biocomposite carrier having a viscosity which is less than and is less rigid than a mixture of minced or milled pretreated allograft cartilage in a biocompatible carrier referred to by the terms “putty” or “paste” and contains less cartilage by weight than putty or paste.

The present invention is directed towards a cartilage repair material and method of treatment. The preferred embodiment and best mode of the invention is shown in FIG. 3. In the production of the invention, allograft hyaline cartilage is lyophilized reducing its water content and milled for ease in application.

After washes with sterile de-ionized (DI) water, the cartilage material was frozen at −20° to −100° C. preferably −70° C. and lyophilized to reduce the water content within the range of about 0.1% to about 8.0%. The cartilage is frozen with liquid nitrogen and ground into particles.

A lesion or defect is removed by cutting a bore 50 or trimming a lesion in the implant area 100 and filling the bore 50 or lesion area with a milled cartilage mixture 20 of paste or gel consisting together with a biological carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers and one or more additives namely chondrogenic stimulating factors including, but not limited to growth factors (FGF-2, FGF-5, IGF-1, TGF-β, BMP-2, BMP-7, PDGF, VEGF), human allogenic or autologous chondrocytes, human allogenic cells, human allogenic or autologous bone marrow cells, human allogenic or autologous stem cells, demineralized bone matrix, insulin, insulin-like growth factor-1, interleukin-1 receptor antagonist, hepatocyte growth factor, platelet-derived growth factor, Indian hedgehog and parathyroid hormone-related peptide.

Suitable organic glue material can be used to keep the viscous cartilage mixture 20 fixed in place in the implant area or to affix a periosteal cap 30 in place over the surrounding hyaline cartilage area 100. Suitable organic glue material can be found commercially, such as for example; TISSEEL® or TISSUCOL®) (fibrin based adhesive; Immuno AG, Austria), Adhesive Protein (Sigma Chemical, USA), and Dow Corning Medical Adhesive B (Dow Corning, USA).

EXAMPLE 1

A matrix of minced cartilage putty consisting of minced or milled allograft articular cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% with a cartilage content ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (molecular weight ranging from 7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers, the carrier ranging from 75% to 50% by weight. The cartilage is milled to a size ranging from 0.01 mm to 1 mm. In gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage when milled is less than or equal to 1 mm dry in the previously stated range. The cartilage pieces can be processed to varying particle sizes and the HA or other carrier can have different viscosities depending on the desired consistency of the putty or paste. This cartilage matrix can be deposited into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, mixed with fibrin glue or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first two matrices, this matrix can support the previously mentioned chondrogenic factors.

EXAMPLE 2

A matrix of minced cartilage putty consisting of minced or milled allograft cartilage which has been lyophilized so that its water content ranges from 0.1% to 8.0% ranging from 25% to 50% by weight is mixed with a carrier of sodium hyaluronate solution (HA) (7.0×105 to 1.2×106) or any other bioabsorbable carrier such as hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered PBS, Dextran, or polymers ranging from 75% to 50% by weight. In a gel form, the minced cartilage which has been lyophilized so that its water content ranges from 0.01% to 8.0% ranging from 15% to 30% by weight and the carrier ranges from 85% to 70% by weight. The particle size of the cartilage is less than or equal to 1 mm dry ranging from 0.01 mm to 1 mm. The cartilage pieces can be processed to varying particle sizes and the HA or carrier can have different viscosities depending on the desired consistency of the putty or paste. Autologous or allogenic cells which have been grown outside the patient are inserted by syringe into the matrix before, during or after deposit of the cartilage matrix into the defect area. Such cells include allogenic or autologous bone marrow cells, stem cells and chondrocyte cells. The cellular density of the cells preferably ranges from about 1×108 to 5×108 or from about 100 million to about 500 million cells per cc of putty or gel mixture. This composite material can be injected into the cartilage defect arthroscopically and fit into the defect where it is held in place by it's own viscosity, or covered with a periosteal or perichondrial flap, then sealed with biological glue. As with the first matrix, this matrix can support the previously mentioned chondrogenic factors.

The operation of placing the cartilage composition in a cartilage defect, comprises (a) cutting a patient's tissue at a site of a cartilage defect to remove the diseased area of cartilage; (b) placing a mixture of milled allograft cartilage in a bioabsorbable carrier in the defect area; and (c) placing a periosteal cover over the mixture of the inserted milled allograft cartilage in a bioabsorbable carrier to contain the mixture in the defect area for a predetermined period of time to promote cartilage growth at the defect site. Alternate steps include the addition of growth factors, chondrocytes, bone marrow cells and stem cells.

The principles, preferred embodiments and modes of operation of the present invention have been described in the foregoing specification. However, the invention should not be construed as limited to the particular embodiments which have been described above. Instead, the embodiments described here should be regarded as illustrative rather than restrictive.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3400199Feb 26, 1965Sep 3, 1968Leslie L. BalassaWound-healing cartilage powder
US3551560Oct 2, 1967Dec 29, 1970Heinrich F ThieleProcess of reconstructing tendons,cartilage,nerve sheaths,and products
US3772432 *Jan 11, 1971Nov 13, 1973Lescarden LtdCartilage compositions for dental use
US3867728Apr 5, 1973Feb 25, 1975Cutter LabProsthesis for spinal repair
US3966908Jul 10, 1975Jun 29, 1976Lescarden Ltd.Method of treating degenerative joint afflictions
US4060081Jul 15, 1975Nov 29, 1977Massachusetts Institute Of TechnologyMultilayer membrane useful as synthetic skin
US4172128May 12, 1977Oct 23, 1979Erhard ThieleProcess of degrading and regenerating bone and tooth material and products
US4201845Feb 6, 1978May 6, 1980Monsanto CompanyCell culture reactor
US4296100Jun 30, 1980Oct 20, 1981Franco Wayne PMethod of treating the heart for myocardial infarction
US4378347Jun 18, 1981Mar 29, 1983Franco Wayne PComposition for treating the heart for myocardial infarction
US4394370Sep 21, 1981Jul 19, 1983Jefferies Steven RBone graft material for osseous defects and method of making same
US4400833Jun 10, 1981Aug 30, 1983Kurland Kenneth ZMeans and method of implanting bioprosthetics
US4442655Jun 25, 1982Apr 17, 1984Serapharm Michael StroetmannFibrinogen-containing dry preparation, manufacture and use thereof
US4458678Oct 26, 1981Jul 10, 1984Massachusetts Institute Of TechnologyCell-seeding procedures involving fibrous lattices
US4479271Oct 26, 1981Oct 30, 1984Zimmer, Inc.Prosthetic device adapted to promote bone/tissue ingrowth
US4501269Feb 21, 1984Feb 26, 1985Washington State University Research Foundation, Inc.Process for fusing bone joints
US4505266Apr 17, 1984Mar 19, 1985Massachusetts Institute Of TechnologyMethod of using a fibrous lattice
US4600574Mar 21, 1984Jul 15, 1986Immuno Aktiengesellschaft Fur Chemisch-Medizinische ProdukteMethod of producing a tissue adhesive
US4627853May 29, 1985Dec 9, 1986American Hospital Supply CorporationMethod of producing prostheses for replacement of articular cartilage and prostheses so produced
US4642120Mar 21, 1984Feb 10, 1987Ramot University Authority For Applied Research And Industrial Development Ltd.Repair of cartilage and bones
US4656137Sep 12, 1985Apr 7, 1987Lescarden IncMethod of processing animal cartilage
US4681763Jun 11, 1985Jul 21, 1987University Of Medicine And Dentistry Of New JerseyComposition for stimulating bone growth
US4683195Feb 7, 1986Jul 28, 1987Cetus CorporationProcess for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202Oct 25, 1985Nov 27, 1990Cetus CorpTitle not available
US4757017Sep 14, 1984Jul 12, 1988Mcw Research Foundation, Inc.In vitro cell culture system
US4776173Jan 26, 1988Oct 11, 1988Angio-Medical CorporationMethod for extracting a substance from animal derived material
US4776853Jul 27, 1987Oct 11, 1988Hsc Research Development CorporationProcess for preparing biological mammalian implants
US4795467Apr 4, 1986Jan 3, 1989Collagen CorporationXenogeneic collagen/mineral preparations in bone repair
US4801299Feb 22, 1984Jan 31, 1989University Patents, Inc.Body implants of extracellular matrix and means and methods of making and using such implants
US4837379Jun 2, 1988Jun 6, 1989Organogenesis Inc.Fibrin-collagen tissue equivalents and methods for preparation thereof
US4846835Jun 15, 1987Jul 11, 1989Grande Daniel ATechnique for healing lesions in cartilage
US4880429Jul 20, 1987Nov 14, 1989Stone Kevin RProsthetic meniscus
US4902508Jul 11, 1988Feb 20, 1990Purdue Research FoundationTissue graft composition
US4904259Dec 5, 1988Feb 27, 1990Samuel ItayCompositions and methods for repair of cartilage and bone
US4932973Apr 21, 1988Jun 12, 1990El GendlerCartilage and bone induction by artificially perforated organic bone matrix
US4950296Jun 13, 1989Aug 21, 1990Mcintyre Jonathan LBone grafting units
US4950483Dec 16, 1988Aug 21, 1990Collagen CorporationCollagen wound healing matrices and process for their production
US4955911Apr 20, 1989Sep 11, 1990Sulzer Brothers LimitedBone implant
US4963146Apr 20, 1989Oct 16, 1990Colla-Tec IncorporatedMulti-layered, semi-permeable conduit for nerve regeneration
US4965188Jun 17, 1987Oct 23, 1990Cetus CorporationProcess for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4971954Nov 23, 1988Nov 20, 1990University Of Medicine And Dentistry Of New JerseyCollagen-based matrices ribose cross-linked
US4976738Dec 2, 1985Dec 11, 1990Sulzer Brothers LimitedPorous metal overlay for an implant surface
US4978355Jan 6, 1986Dec 18, 1990Sulzer Brothers LimitedPlastic bone implant having a reinforced contact surface
US4994084Jun 23, 1989Feb 19, 1991Brennan H GeorgeReconstructive surgery method and implant
US4994559Jan 26, 1989Feb 19, 1991Synergen, Inc.Human basic fibroblast growth factor
US5002583Aug 8, 1986Mar 26, 1991Sandu PitaruCollagen implants
US5007934Mar 2, 1989Apr 16, 1991Regen CorporationProsthetic meniscus
US5041138Apr 17, 1989Aug 20, 1991Massachusetts Institute Of TechnologyNeomorphogenesis of cartilage in vivo from cell culture
US5053049May 29, 1985Oct 1, 1991Baxter InternationalFlexible prostheses of predetermined shapes and process for making same
US5053050Apr 29, 1988Oct 1, 1991Samuel ItayCompositions for repair of cartilage and bone
US5067964Dec 13, 1989Nov 26, 1991Stryker CorporationArticular surface repair
US5073373Sep 21, 1989Dec 17, 1991Osteotech, Inc.Flowable demineralized bone powder composition and its use in bone repair
US5084051Nov 3, 1987Jan 28, 1992Toermaelae PerttiLayered surgical biocomposite material
US5118512Jan 23, 1990Jun 2, 1992Osteotech, Inc. (A Delaware Corp.)Process for cryopreserving biological materials and materials prepared thereby
US5152791Feb 18, 1992Oct 6, 1992Olympus Optical Co., Ltd.Prosthetic artificial bone having ceramic layers of different porosity
US5155214Jan 8, 1990Oct 13, 1992The Salk Institute For Biological StudiesBasic fibroblast growth factor
US5191067Apr 27, 1989Mar 2, 1993The Salk Institute For Biological StudiesFibroblast growth factor conjugates
US5195892Jul 23, 1991Mar 23, 1993Odontit S.A.Bone-integrated dental implant system
US5206023Jan 31, 1991Apr 27, 1993Robert F. ShawMethod and compositions for the treatment and repair of defects or lesions in cartilage
US5236456Jan 17, 1991Aug 17, 1993Osteotech, Inc.Osteogenic composition and implant containing same
US5256140Mar 27, 1992Oct 26, 1993Fallien Cosmeceuticals, Ltd.Composition for levelling skin
US5260420Apr 24, 1992Nov 9, 1993Centre Regional De Transfusion Sanguine De LilleConcentrate of thrombin coagulable proteins, the method of obtaining same and therapeutical use thereof
US5266476Apr 14, 1992Nov 30, 1993Yeda Research & Development Co., Ltd.Fibrous matrix for in vitro cell cultivation
US5270300Sep 6, 1991Dec 14, 1993Robert Francis ShawMethods and compositions for the treatment and repair of defects or lesions in cartilage or bone
US5275826Nov 13, 1992Jan 4, 1994Purdue Research FoundationFluidized intestinal submucosa and its use as an injectable tissue graft
US5284155 *Dec 6, 1991Feb 8, 1994The General Hospital CorporationCartilage degradation assay system
US5290558Aug 27, 1990Mar 1, 1994Osteotech, Inc.Flowable demineralized bone powder composition and its use in bone repair
US5298254Dec 17, 1991Mar 29, 1994Osteotech, Inc.Shaped, swollen demineralized bone and its use in bone repair
US5302702Feb 26, 1993Apr 12, 1994American Cyanamid CompanyChimeric fibroblast growth factors
US5306304Jan 13, 1993Apr 26, 1994El GendlerFlexible membranes produced from organic bone matrix for skeletal repair and reconstruction
US5306311Dec 17, 1991Apr 26, 1994Regen CorporationProsthetic articular cartilage
US5310883Nov 4, 1991May 10, 1994American Cyanamid CompanyChimeric fibroblast growth factors
US5314476Sep 10, 1993May 24, 1994Osteotech, Inc.Demineralized bone particles and flowable osteogenic composition containing same
US5326357Mar 18, 1992Jul 5, 1994Mount Sinai Hospital CorporationReconstituted cartridge tissue
US5329846Aug 12, 1991Jul 19, 1994Bonutti Peter MTissue press and system
US5336616Feb 2, 1993Aug 9, 1994Lifecell CorporationMethod for processing and preserving collagen-based tissues for transplantation
US5338772Jun 22, 1992Aug 16, 1994Merck Patent Gesellschaft Mit Beschrankter HaftungImplant material
US5352463Nov 13, 1992Oct 4, 1994Badylak Steven FTissue graft for surgical reconstruction of a collagenous meniscus and method therefor
US5354557Dec 18, 1992Oct 11, 1994Stryker CorporationOsteogenic devices
US5356629Jul 12, 1991Oct 18, 1994United States Surgical CorporationComposition for effecting bone repair
US5368858Nov 23, 1992Nov 29, 1994Robert F. ShawMethods and compositions for the treatment and repair of defects or lesions in cartilage
US5380328Aug 9, 1993Jan 10, 1995Timesh, Inc.Composite perforated implant structures
US5411885Dec 17, 1993May 2, 1995New York Blood Center, Inc.Methods for tissue embedding and tissue culturing
US5425769Mar 4, 1993Jun 20, 1995Snyders, Jr.; Robert V.Composition of material for osseous repair
US5439684Jan 21, 1994Aug 8, 1995Osteotech, Inc.Shaped, swollen demineralized bone and its use in bone repair
US5439818Dec 16, 1985Aug 8, 1995Scios Nova Inc.DNA encoding human recombinant basic fibroblast growth factor
US5443950Oct 4, 1993Aug 22, 1995Advanced Tissue Sciences, Inc.Three-dimensional cell and tissue culture system
US5464439Nov 12, 1993Nov 7, 1995Gendler; ElFlexible membranes produced from organic bone matrix for skeletal repair and reconstruction
US5466462Mar 22, 1993Nov 14, 1995Johnson & Johnson Medical, Inc.Heteromorphic sponges containing active agents
US5491220Aug 15, 1994Feb 13, 1996Yeda Research And Development Co., Ltd.Surface loop structural analogues of fibroblast growth factors
US5496722May 25, 1993Mar 5, 1996The United States Of America As Represented By The Administrator Of The National Aeronautics And Space AdministrationMethod for producing non-neoplastic, three dimensional, mammalian tissue and cell aggregates under microgravity culture conditions and the products produced therefrom
US5507813Dec 9, 1993Apr 16, 1996Osteotech, Inc.Shaped materials derived from elongate bone particles
US5512460Nov 17, 1994Apr 30, 1996Takeda Chemical Industries, LdtGlia activating factor and its production
US5513662Jan 21, 1994May 7, 1996Osteotech, Inc.Preparation of bone for transplantation
US5516532Aug 5, 1994May 14, 1996Children's Medical Center CorporationInjectable non-immunogenic cartilage and bone preparation
US5556430Jun 6, 1995Sep 17, 1996Gendler; ElFlexible membranes produced from organic bone matrix for skeletal repair and reconstruction
US5569272Feb 8, 1994Oct 29, 1996Carnegie Mellon UniversityTissue-connective devices with micromechanical barbs
US5571895Dec 21, 1993Nov 5, 1996Takeda Chemical Industries, Ltd.Modified GAF polypeptides
US5576288Jun 10, 1994Nov 19, 1996The Salk Institute For Biological StudiesFibroblast growth factor conjugates
US5604293Apr 1, 1994Feb 18, 1997Scios Inc.Recombinant human basic fibroblast growth factor
US5607474Sep 20, 1993Mar 4, 1997Board Of Regents, University Of Texas SystemMulti-phase bioerodible implant/carrier and method of manufacturing and using same
US5614496Jun 2, 1995Mar 25, 1997Osteosa Inc.Use of fibroblast growth factors to stimulate bone growth
US5618925Feb 3, 1995Apr 8, 1997Les Laboratories Aeterna Inc.Extracts of shark cartilage having an anti-angiogenic activity and an effect on tumor regression; process of making thereof
US5622928Jan 24, 1996Apr 22, 1997Takeda Chemical Industries, Ltd.Glia activation factor and its production
US5624463Apr 25, 1994Apr 29, 1997Regen Biologics, Inc.Prosthetic articular cartilage
US5631011Jun 17, 1992May 20, 1997Wadstroem; JonasTissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US5632745Feb 7, 1995May 27, 1997R&D Biologicals, Inc.Surgical implantation of cartilage repair unit
US5656598May 31, 1995Aug 12, 1997Rhone-Poulenc Rorer Pharmaceuticals Inc.Use of fibroblast growth factors to stimulate bone growth
US5662710Jan 23, 1996Sep 2, 1997Bonutti; Peter M.Tissue press method of use
US5679637Jun 5, 1995Oct 21, 1997The Salk Institute For Biological StudiesFibroblast growth factor conjugates
US5695998Feb 10, 1995Dec 9, 1997Purdue Research FoundationSubmucosa as a growth substrate for islet cells
US5700476Feb 24, 1995Dec 23, 1997Johnson & Johnson Medical, Inc.Heteromorphic sponges containing active agents
US5700774Mar 26, 1996Dec 23, 1997Genetics Institute, Inc.Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same
US5707962Sep 28, 1994Jan 13, 1998Gensci Regeneration Sciences Inc.Compositions with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US5713374Feb 10, 1995Feb 3, 1998The Hospital For Joint Diseases Orthopaedic InstituteFixation method for the attachment of wound repair materials to cartilage defects
US5716413Oct 11, 1995Feb 10, 1998Osteobiologics, Inc.Moldable, hand-shapable biodegradable implant material
US5723331Jun 6, 1995Mar 3, 1998Genzyme CorporationMethods and compositions for the repair of articular cartilage defects in mammals
US5736372Apr 16, 1990Apr 7, 1998Massachusetts Institute Of TechnologyBiodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
US5749874Dec 30, 1996May 12, 1998Matrix Biotechnologies, Inc.Cartilage repair unit and method of assembling same
US5759190Aug 30, 1996Jun 2, 1998Vts Holdings LimitedMethod and kit for autologous transplantation
US5769899Aug 15, 1996Jun 23, 1998Matrix Biotechnologies, Inc.Cartilage repair unit
US5770417Feb 28, 1994Jun 23, 1998Massachusetts Institute Of Technology Children's Medical Center CorporationThree-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo
US5782835Mar 7, 1995Jul 21, 1998Innovasive Devices, Inc.Apparatus and methods for articular cartilage defect repair
US5782915Jan 6, 1997Jul 21, 1998Stone; Kevin R.Articular cartilage heterografts
US5786217Apr 14, 1997Jul 28, 1998Genzyme CorporationMethods and compositions for the repair of articular cartilage defects in mammals
US5800537Jun 6, 1995Sep 1, 1998Tissue Engineering, Inc.Method and construct for producing graft tissue from an extracellular matrix
US5814084Jan 16, 1996Sep 29, 1998University Of Florida Tissue Bank, Inc.Diaphysial cortical dowel
US5842477 *Feb 21, 1996Dec 1, 1998Advanced Tissue Sciences, Inc.Method for repairing cartilage
US5846931Sep 10, 1997Dec 8, 1998Hattersley; GaryCompositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide and methods of inducing cartilage by administration of same
US5853746Jun 28, 1996Dec 29, 1998Robert Francis ShawMethods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
US5855620Oct 30, 1996Jan 5, 1999St. Jude Medical, Inc.Matrix substrate for a viable body tissue-derived prosthesis and method for making the same
US5859208Jul 6, 1988Jan 12, 1999Fiddes; John C.Human basic fibroblast growth factor analog
US5863296Jun 5, 1995Jan 26, 1999Colorado State University Research FoundationTreated tissue for implantation and methods of treatment and use
US5863297Oct 8, 1996Jan 26, 1999Osteobiologics, Inc.Moldable, hand-shapable biodegradable implant material
US5866415Mar 25, 1997Feb 2, 1999Villeneuve; Peter E.Materials for healing cartilage and bone defects
US5876452May 30, 1995Mar 2, 1999Board Of Regents, University Of Texas SystemBiodegradable implant
US5888219Apr 11, 1997Mar 30, 1999Bonutti; Peter M.Method of using human tissue with a tissue press and system
US5893888Sep 6, 1994Apr 13, 1999Tissue Engineering, Inc.Method and construct for producing graft tissue from extracellular matrix
US5899936Jun 5, 1995May 4, 1999Cryolife, Inc.Treated tissue for implantation and methods of preparation
US5904716Apr 26, 1995May 18, 1999Gendler; ElMethod for reconstituting cartilage tissue using demineralized bone and product thereof
US5906827Jun 3, 1994May 25, 1999Creative Biomolecules, Inc.Matrix for the manufacture of autogenous replacement body parts
US5910315Jul 18, 1997Jun 8, 1999Stevenson; SharonAllograft tissue material for filling spinal fusion cages or related surgical spaces
US5916265Jun 6, 1995Jun 29, 1999Hu; JieMethod of producing a biological extracellular matrix for use as a cell seeding scaffold and implant
US5948429Nov 16, 1995Sep 7, 1999Tissue Engineering, Inc.Methods for preparing biopolymer foams
US5955438Jul 19, 1995Sep 21, 1999Colbar R & D Ltd.Collagen-based matrix
US5964805Aug 7, 1997Oct 12, 1999Stone; Kevin R.Method and paste for articular cartilage transplantation
US5968556Apr 2, 1996Oct 19, 1999Children's Medical Center Corp.Injectable non-immunogenic cartilage and bone preparation
US5972368Jun 11, 1997Oct 26, 1999Sdgi Holdings, Inc.Bone graft composites and spacers
US5972385Jan 15, 1998Oct 26, 1999Orquest, Inc.Collagen-polysaccharide matrix for bone and cartilage repair
US5974663Oct 22, 1997Nov 2, 1999Honda Giken Kogya Kabushiki KaishaMethod of manufacturing connecting rod
US5989269May 15, 1997Nov 23, 1999Vts Holdings L.L.C.Method, instruments and kit for autologous transplantation
US5989289Oct 9, 1997Nov 23, 1999Sdgi Holdings, Inc.Bone grafts
US5989866Oct 16, 1997Nov 23, 1999Zymogenetics, Inc.FGF homologs
US5998170Oct 3, 1997Dec 7, 1999Amgen Inc.Polynucleotides encoding hepatocyte-specific members of the FGF family
US6001352Mar 31, 1997Dec 14, 1999Osteobiologics, Inc.Resurfacing cartilage defects with chondrocytes proliferated without differentiation using platelet-derived growth factor
US6005161Jun 7, 1995Dec 21, 1999Thm Biomedical, Inc.Method and device for reconstruction of articular cartilage
US6013853Feb 15, 1994Jan 11, 2000The University Of Texas SystemContinuous release polymeric implant carrier
US6017348May 30, 1997Jan 25, 2000Innovasive Devices, Inc.Apparatus and methods for articular cartilage defect repair
US6025334Oct 30, 1995Feb 15, 2000Les Laboratoires Aeterna Inc.Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof
US6025538Nov 20, 1998Feb 15, 2000Musculoskeletal Transplant FoundationCompound bone structure fabricated from allograft tissue
US6027743Jun 2, 1995Feb 22, 2000Stryker CorporationManufacture of autogenous replacement body parts
US6030635Feb 27, 1998Feb 29, 2000Musculoskeletal Transplant FoundationMalleable paste for filling bone defects
US6037171Sep 25, 1996Mar 14, 2000Microcloning Cccd AbCell culture microchambers in a grid matrix sandwiched between a planar base and semipermeable membrane
US6039762Jun 11, 1997Mar 21, 2000Sdgi Holdings, Inc.Reinforced bone graft substitutes
US6060640May 19, 1995May 9, 2000Baxter International Inc.Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue
US6074663Jan 16, 1996Jun 13, 2000Baxter International Inc.Method of using cross-linked fibrin material
US6080194Feb 10, 1995Jun 27, 2000The Hospital For Joint Disease Orthopaedic InstituteMulti-stage collagen-based template or implant for use in the repair of cartilage lesions
US6090996Aug 4, 1997Jul 18, 2000Collagen Matrix, Inc.Implant matrix
US6090998Oct 27, 1997Jul 18, 2000University Of FloridaSegmentally demineralized bone implant
US6096081Jan 16, 1997Aug 1, 2000University Of Florida Tissue Bank, Inc.Diaphysial cortical dowel
US6096347Nov 4, 1997Aug 1, 2000Purdue Research FoundationMyocardial graft constructs
US6110209Nov 5, 1998Aug 29, 2000Stone; Kevin R.Method and paste for articular cartilage transplantation
US6110482Jun 2, 1995Aug 29, 2000Styker CorporationManufacture of autogenous replacement body parts
US6123731Feb 6, 1998Sep 26, 2000Osteotech, Inc.Osteoimplant and method for its manufacture
US6132472Mar 5, 1999Oct 17, 2000Bonutti; Peter M.Tissue press and system
US6143293Mar 26, 1998Nov 7, 2000Carnegie MellonAssembled scaffolds for three dimensional cell culturing and tissue generation
US6156068Jan 21, 1999Dec 5, 2000Osteobiologics, Inc.Method of resurfacing a femoral condyle
US6165486Nov 19, 1998Dec 26, 2000Carnegie Mellon UniversityBiocompatible compositions and methods of using same
US6165487Apr 9, 1998Dec 26, 2000Children's Medical Center CorporationMethods and compositions for programming an organic matrix for remodeling into a target tissue
US6180605Jan 5, 1998Jan 30, 2001Gensci Orthobiologics, Inc.Composition with enhanced osteogenic potential, method for making the same and therapeutic uses thereof
US6183737Oct 29, 1998Feb 6, 2001The General Hospital CorporationBonding of cartilage pieces using isolated chondrocytes and a biological gel
US6189537Sep 6, 1996Feb 20, 2001LifenetProcess for producing osteoinductive bone, and osteoinductive bone produced thereby
US6197586Dec 3, 1998Mar 6, 2001The Regents Of The University Of CaliforniaChondrocyte-like cells useful for tissue engineering and methods
US6200347Aug 3, 1999Mar 13, 2001LifenetComposite bone graft, method of making and using same
US6221854Jul 26, 1999Apr 24, 2001Orquest, Inc.Method of promoting bone growth with hyaluronic acid and growth factors
US6231607Dec 19, 1996May 15, 2001Hadasit Medical Research Services & Development Company Ltd.Bone graft substitute and its preparation
US6235316Apr 3, 1998May 22, 2001Barnes-Jewish HospitalNeocartilage and methods of use
US6242247Jun 2, 1997Jun 5, 2001Sulzer Orthopedics Ltd.Method for making cartilage and implants
US6251143Jun 4, 1999Jun 26, 2001Depuy Orthopaedics, Inc.Cartilage repair unit
US6258778Jul 12, 1999Jul 10, 2001University Of Southern CaliforniaMethods for accelerating bone and cartilage growth and repair
US6261586Aug 31, 1999Jul 17, 2001Sdgi Holdings, Inc.Bone graft composites and spacers
US6267786Feb 11, 1999Jul 31, 2001Crosscart, Inc.Proteoglycan-reduced soft tissue xenografts
US6270528Aug 6, 1999Aug 7, 2001Sdgi Holdings, Inc.Composited intervertebral bone spacers
US6274090Aug 5, 1998Aug 14, 2001Thermogenesis Corp.Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby
US6274663Oct 30, 1997Aug 14, 2001Showa Denko K.K.Compound resin composition
US6274712Dec 23, 1998Aug 14, 20013-Dimensional Pharmaceuticals, Inc.Analogs of human basic fibroblast growth factor mutated at one or more of the positions glutamute 89, aspartate 101 or leucine 137
US6280473Feb 23, 1999Aug 28, 2001Macropore, Inc.Resorbable, macro-porous, non-collapsing and flexible membrane barrier for skeletal repair and regeneration
US6281195Feb 5, 1998Aug 28, 2001Stryker CorporationMatrix-free osteogenic devices, implants and methods of use thereof
US6283980May 26, 1999Sep 4, 2001Verigen Transplantation Services Internt'lMethod, instruments, and kit for autologous transplantation
US6293970Jun 30, 1998Sep 25, 2001LifenetPlasticized bone and soft tissue grafts and methods of making and using same
US6294187Feb 23, 1999Sep 25, 2001Osteotech, Inc.Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same
US6294359Jun 16, 1998Sep 25, 2001Scios Inc.Human basic fibroblast growth factor analog
US6303585Jul 1, 1998Oct 16, 2001Orquest, Inc.Cross-linked polysaccharide drug carrier
US6305379Apr 12, 2000Oct 23, 2001LifenetProcess for producing osteoinductive bone, and osteoinductive bone produced thereby
US6306174Dec 16, 1999Oct 23, 2001Benoist Girard SasFemoral component
US6306424Dec 21, 1999Oct 23, 2001Ethicon, Inc.Foam composite for the repair or regeneration of tissue
US6310267Nov 5, 1999Oct 30, 2001Aventis Behring GmbhFlexible wound covering based on fibrin and process for its production
US6319712Jan 26, 1999Nov 20, 2001Deutsche Institute Fur Textil-Und Faserforschung StuttgartBiohybrid articular surface replacement
US6333029Jun 30, 1999Dec 25, 2001Ethicon, Inc.Porous tissue scaffoldings for the repair of regeneration of tissue
US6352558Dec 29, 1999Mar 5, 2002Ed. Geistlich Soehne Ag Fuer Chemische IndustrieMethod for promoting regeneration of surface cartilage in a damage joint
US6352971Aug 5, 1999Mar 5, 2002Zymogenetics, Inc.FGF Homologs
US6361565Jun 23, 2000Mar 26, 2002Peter M. BonuttiExpandable hip implant
US6376244Dec 29, 1999Apr 23, 2002Children's Medical Center CorporationMethods and compositions for organ decellularization
US6379367Oct 17, 2000Apr 30, 2002Verigen Transplantation Service International (Vtsi) AgMethod instruments and kit for autologous transplantation
US6379385Jan 6, 2000Apr 30, 2002Tutogen Medical GmbhImplant of bone matter
US6383221Aug 8, 2001May 7, 2002Osteotech, Inc.Method for forming an intervertebral implant
US6387693Apr 18, 2001May 14, 2002Sulzer Orthopedics Ltd.Method for producing cartilage tissue and implants for repairing enchondral and osteochondral defects as well as arrangement for carrying out the method
US6398811Jun 1, 2001Jun 4, 2002Sdgi Holdings, Inc.Composited intervertebral bone spacers
US6398816Jan 21, 2000Jun 4, 2002North Shore-Long Island Jewish Research InstituteGenetic engineering of cells to enhance healing and tissue regeneration
US6398972Apr 11, 2000Jun 4, 2002Harvest Technologies CorporationMethod for producing platelet rich plasma and/or platelet concentrate
US6432436Dec 19, 2000Aug 13, 2002Musculoskeletal Transplant FoundationPartially demineralized cortical bone constructs
US6437018Feb 29, 2000Aug 20, 2002Musculoskeletal Transplant FoundationMalleable paste with high molecular weight buffered carrier for filling bone defects
US6440141Jul 24, 2000Aug 27, 2002Oratec Interventions, Inc.Method and apparatus for treating osteochondral pathologies
US6440427Dec 19, 1997Aug 27, 2002Biovitrum AbTissue treatment composition comprising fibrin or fibrinogen and biodegradable and biocompatible polymer
US6440444Jul 24, 2001Aug 27, 2002Osteotech, Inc.Load bearing osteoimplant and method of repairing bone using the same
US6454811Oct 12, 1999Sep 24, 2002Massachusetts Institute Of TechnologyComposites for tissue regeneration and methods of manufacture thereof
US6458144Jan 2, 2001Oct 1, 2002Osteotech, Inc.Methods for manufacturing skeletal implants
US6458158Oct 27, 2000Oct 1, 2002LifenetComposite bone graft, method of making and using same
US6458375Oct 3, 2000Oct 1, 2002Musculoskeletal Transplant FoundationMalleable paste with allograft bone reinforcement for filling bone defects
US6468314Mar 8, 2001Oct 22, 2002Depuy Orthopaedics, Inc.Cartilage repair unit
US6471993Jul 31, 1998Oct 29, 2002Massachusetts Institute Of TechnologyThree-dimensional polymer matrices
US6475175Apr 8, 1999Nov 5, 2002John RiveraMethod and apparatus for sequestering platelet rich plasma
US6486377May 2, 2001Nov 26, 2002Aventis Behring GmbhFlexible wound covering based on fibrin and process for its production
US6488033May 15, 2000Dec 3, 2002Cryolife, Inc.Osteochondral transplant techniques
US6489165Jan 16, 2001Dec 3, 2002The Regents Of The University Of CaliforniaChondrocyte-like cells useful for tissue engineering and methods
US6497726Jan 11, 2000Dec 24, 2002Regeneration Technologies, Inc.Materials and methods for improved bone tendon bone transplantation
US6503277Mar 1, 2001Jan 7, 2003Peter M. BonuttiMethod of transplanting human body tissue
US6511511Oct 25, 1999Jan 28, 2003Osteobiologics, Inc.Fiber-reinforced, porous, biodegradable implant device
US6511958Feb 16, 2000Jan 28, 2003Sulzer Biologics, Inc.Compositions for regeneration and repair of cartilage lesions
US6514514Feb 16, 1999Feb 4, 2003Sùlzer Biologics Inc.Device and method for regeneration and repair of cartilage lesions
US6520964May 1, 2001Feb 18, 2003Std Manufacturing, Inc.System and method for joint resurface repair
US6530956Sep 10, 1999Mar 11, 2003Kevin A. MansmannResorbable scaffolds to promote cartilage regeneration
US6534084Dec 19, 2000Mar 18, 2003Ethicon, Inc.Porous tissue scaffoldings for the repair or regeneration of tissue
US6541024Mar 13, 1998Apr 1, 2003Osiris Therapeutics, Inc.Regeneration and augmentation of bone using mesenchymal stem cells
US6548729Sep 18, 1998Apr 15, 2003Baxter AktiengesellschaftFibrin sponge
US6569172Oct 3, 2001May 27, 2003Verigen Transplantation Service International (Vtsi)Method, instruments, and kit for autologous transplantation
US6576015Jul 18, 2001Jun 10, 2003Ed. Geistlich Soehne Ag Fuer Chemische IndustrieBone material and collagen combination for repair of injured joints
US6582960Sep 17, 1999Jun 24, 2003Massachusetts Institute Of TechnologyUse of fibroblast growth factor 2 for expansion of chondrocytes and tissue engineering
US6591581Mar 8, 2001Jul 15, 2003Arthrex, Inc.Method for preparing and inserting round, size specific osteochondral cores in the knee
US6592598Jan 23, 2002Jul 15, 2003Verigen Transplantation Service International (Vtsi)Method, instruments, and kit for autologous transplantation
US6592599Mar 5, 2002Jul 15, 2003Verigen Transplantation Service International (Vtsi)Method, instruments, and kit for autologous transplantation
US6599300Mar 4, 2002Jul 29, 2003Verigen Transplantation Service International (Vtsi)Method, instruments, and kit for autologous transplantation
US6599301Mar 6, 2002Jul 29, 2003Verrgen Transplantation Service International (Vtsi)Method, instruments, and kit for autologous transplantation
US6599515May 8, 2000Jul 29, 2003Baxter International Inc.Fibrin porous structure
US6623963Dec 20, 1999Sep 23, 2003Verigen AgCellular matrix
US6626950Jun 28, 2001Sep 30, 2003Ethicon, Inc.Composite scaffold with post anchor for the repair and regeneration of tissue
US6630000Nov 19, 1999Oct 7, 2003Bonutti 2003 Trust-AMethod of using body tissue
US6632247Mar 22, 2001Oct 14, 2003Synthes (Usa)Implants formed of coupled bone
US6652592Oct 13, 1999Nov 25, 2003Regeneration Technologies, Inc.Segmentally demineralized bone implant
US6652593Aug 13, 2001Nov 25, 2003Synthes (Usa)Demineralized bone implants
US6652872Apr 4, 2001Nov 25, 2003Ramat At Tel Aviv University Ltd.Scaffold formed of tissue treated to eliminate cellular and cytosolic elements
US6662805Aug 6, 2001Dec 16, 2003The Johns Hopkins UniversityMethod for composite cell-based implants
US6666892May 27, 1999Dec 23, 2003Cook Biotech IncorporatedMulti-formed collagenous biomaterial medical device
US6686184May 25, 2000Feb 3, 2004President And Fellows Of Harvard CollegePatterning of surfaces utilizing microfluidic stamps including three-dimensionally arrayed channel networks
US6689747Mar 22, 2001Feb 10, 2004Genentech, Inc.Use of insulin for the treatment of cartilagenous disorders
US6696073Aug 27, 2002Feb 24, 2004Osteotech, Inc.Shaped load-bearing osteoimplant and methods of making same
US6712851May 25, 2001Mar 30, 2004Macropore Biosurgery, Inc.Resorbable, macro-porous non-collapsing and flexible membrane barrier for skeletal repair and regeneration
US6727224Jan 28, 2000Apr 27, 2004Genetics Institute, Llc.Methods and compositions for healing and repair of articular cartilage
US6730314Aug 29, 2001May 4, 2004Merck Patent GesellschaftCulturing encapsulated chondrocytes under reduced oxygen partial pressure to produce cartilage implants
US6734018Mar 17, 2000May 11, 2004LifenetProcess for decellularizing soft-tissue engineered medical implants, and decellularized soft-tissue medical implants produced
US6743232Feb 26, 2001Jun 1, 2004David W. OverakerTissue scaffold anchor for cartilage repair
US6752834Apr 7, 2000Jun 22, 2004Ed Geistlich Soehne Ag Fuer Chemische IndustrieMembrane for in guided tissue regeneration
US6761739Nov 25, 2002Jul 13, 2004Musculoskeletal Transplant FoundationCortical and cancellous allograft spacer
US6761887Nov 16, 1999Jul 13, 2004Osiris Therapeutics, Inc.Alginate layer system for chondrogenic differentiation of human mesenchymal stem cells
US6767369Mar 22, 2001Jul 27, 2004Synthes (Usa)Plugs for filling bony defects
US6776800Aug 13, 2001Aug 17, 2004Synthes (U.S.A.)Implants formed with demineralized bone
US6783712Nov 4, 2002Aug 31, 2004Osteobiologics, Inc.Fiber-reinforced, porous, biodegradable implant device
US6808585Oct 9, 2001Oct 26, 2004Osteotech, Inc.Osteogenic implants derived from bone
US6815416Jul 19, 2001Nov 9, 2004The Board Of Regents, The University Of Texas SystemStimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
US6838440Jan 24, 2001Jan 4, 2005Collagen Nutraceuticals, Inc.Kolla2-desiccated avian sternal cartilage powder
US6841150Apr 18, 2002Jan 11, 2005Artecal, Sciences, Inc.Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
US6852114Feb 28, 2002Feb 8, 2005Cryolife, Inc.Osteochondral transplant techniques
US6852125Aug 28, 2003Feb 8, 2005Chondrosite, Inc.Cartilage repair plug
US6852331Feb 11, 2002Feb 8, 2005Taipei Biotechnology Ltd., Inc.Fabrication of a cartilage implant
US6855167Dec 5, 2001Feb 15, 2005Osteotech, Inc.Spinal intervertebral implant, interconnections for such implant and processes for making
US6855169Aug 13, 2001Feb 15, 2005Synthes (Usa)Demineralized bone-derived implants
US6858042Dec 12, 2000Feb 22, 2005Zimmer Orthobiologics, Inc.Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
US6866668May 17, 2001Mar 15, 2005Verigen Transplantation Service International (“VTSL”) AGMethods, instruments and materials for chondrocyte cell transplantation
US6884428Dec 16, 2002Apr 26, 2005Depuy Mitek, Inc.Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration
US6890354Mar 8, 2002May 10, 2005Musculoskeletal Transplant FoundationBone-tendon-bone assembly with allograft bone block and method for inserting same
US6893462Aug 29, 2001May 17, 2005Regeneration Technologies, Inc.Soft and calcified tissue implants
US6902578Oct 27, 2000Jun 7, 2005LifenetComposite bone graft, method of making and using same
US6911212Oct 24, 2001Jun 28, 2005Musculoskeletal Transplant FoundationMalleable putty and flowable paste with allograft bone having residual calcium for filling bone defects
US6932977Mar 13, 2001Aug 23, 2005Depuy Spine, Inc.Method of inducing or enhancing chondrogenesis with extracellular matrix containing BMP-4
US6933326Jun 18, 1999Aug 23, 2005Lifecell CoporationParticulate acellular tissue matrix
US6933328Apr 3, 2001Aug 23, 2005Universiteit GentComposition of crosslinkable prepolymers for biodegradable implants
US6949252Mar 22, 2002Sep 27, 2005Histogenics, Corp.Method for preparing an implantable multilayer tissue construct
US6989034May 31, 2002Jan 24, 2006Ethicon, Inc.Attachment of absorbable tissue scaffolds to fixation devices
US6995013Jul 8, 2002Feb 7, 2006Biomed Solutions, LlcCell-scaffold composition containing five layers
US7009039Jan 20, 2004Mar 7, 2006Prochon Biotech Ltd.Plasma protein matrices and methods for their preparation
US7018416Feb 19, 2002Mar 28, 2006Zimmer Spine, Inc.Bone implants and methods
US7033587Nov 1, 2004Apr 25, 2006Artecel Sciences, Inc.Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
US7041641Mar 20, 1997May 9, 2006Stryker CorporationOsteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
US7044968Feb 14, 2000May 16, 2006Musculoskeletal Transplant FoundationCompound bone structure of allograft tissue with threaded fasteners
US7045141May 20, 2002May 16, 2006Musculoskeletal Transplant FoundationAllograft bone composition having a gelatin binder
US7048750May 23, 2003May 23, 2006Verigen AgMethod, instruments, and kits for autologous transplantation
US7048762Aug 27, 1998May 23, 2006Regeneration Technologies, Inc.Elongated cortical bone implant
US7048765Nov 25, 2000May 23, 2006Regeneration Technologies, Inc.Intervertebral spacers
US7067123Apr 29, 2003Jun 27, 2006Musculoskeletal Transplant FoundationGlue for cartilage repair
US7070942Nov 5, 2004Jul 4, 2006Depuy Spine, Inc.Method of inducing or enhancing chondrogenesis with extracellular matrix containing GDF-5
US7078232Jan 14, 2003Jul 18, 2006Artecel, Inc.Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US7108721May 10, 2001Sep 19, 2006Massachusetts Institute Of TechnologyTissue regrafting
US7115146Mar 22, 2001Oct 3, 2006Boyer Ii Michael LMultipiece implants formed of bone material
US7125423Mar 31, 2003Oct 24, 2006Depuy Products, Inc.Intercalary prosthesis, kit and method
US7132110Jul 15, 2002Nov 7, 2006Isotis Orthobiologics, Inc.Tissue repair compositions and methods for their manufacture and use
US7137989Mar 26, 2003Nov 21, 2006Verigen AgMethod, instruments, and kit for autologous transplantation
US7141072Aug 10, 2001Nov 28, 2006Ed. Geistlich Soehne Ag Fuer Chemische IndustrieMethod for promoting regeneration of surface cartilage in a damaged joint using multi-layer covering
US7156880Aug 14, 2003Jan 2, 2007Kensey Nash CorporationDevices and methods for treating defects in the tissue of a living being
US7157428Nov 26, 2004Jan 2, 2007Histogenics, Corp.Method for treatment and repair of meniscal injuries
US7163563Jul 15, 2002Jan 16, 2007Depuy Products, Inc.Unitary surgical device and method
US7166133Jun 13, 2002Jan 23, 2007Kensey Nash CorporationDevices and methods for treating defects in the tissue of a living being
US7179299Nov 1, 2002Feb 20, 2007Osteotech, Inc.Osteoimplant and method for making same
US7182781Nov 1, 2000Feb 27, 2007Regeneration Technologies, Inc.Cervical tapered dowel
US7201917Jul 15, 2002Apr 10, 2007Depuy Products, Inc.Porous delivery scaffold and method
US7217294Jun 30, 2004May 15, 2007Histogenics Corp.Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof
US7220558Mar 3, 2003May 22, 2007The United States Of America As Represented By The Department Of Health And Human ServicesCartilage-derived morphogenetic proteins
US7241316Jul 31, 2003Jul 10, 2007Douglas G EvansDevices and methods for treating defects in the tissue of a living being
US7252987Dec 6, 2002Aug 7, 2007Islet Technology, Inc.System for analysis and selection of encapsulated cellular materials
US7264634Sep 22, 2003Sep 4, 2007Arthrex, Inc.Method and instrumentation for osteochondral repair using preformed implants
US7288406Apr 29, 2003Oct 30, 2007Prochon Biotech Ltd.Active variants of FGF with improved specificity
US7291169Apr 15, 2005Nov 6, 2007Zimmer Technology, Inc.Cartilage implant
US7297161Apr 26, 2004Nov 20, 2007Fell Barry MSurgically implantable knee prosthesis
US7316822Nov 26, 2003Jan 8, 2008Ethicon, Inc.Conformable tissue repair implant capable of injection delivery
US7323011Oct 18, 2002Jan 29, 2008Musculoskeletal Transplant FoundationCortical and cancellous allograft cervical fusion block
US7323445Feb 18, 2004Jan 29, 2008Genetics Institute, LlcMethods and compositions for healing and repair of articular cartilage
US7335508Jul 22, 2004Feb 26, 2008Prochon Biotech Ltd.Porous plasma protein matrices and methods for preparation thereof
US7338492Oct 24, 2003Mar 4, 2008Linvatec CorporationCross-pin graft fixation, instruments, and methods
US7338524Apr 22, 2004Mar 4, 2008Fell Barry MSurgically implantable knee prosthesis
US7358284Jan 20, 2005Apr 15, 2008Lifecell CorporationParticulate acellular tissue matrix
US7361195Jul 15, 2002Apr 22, 2008Depuy Products, Inc.Cartilage repair apparatus and method
US7365051Mar 16, 2005Apr 29, 2008Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka MbhCompounds with improved cartilage-inducing and/or bone-inducing activity
US7371400Jan 2, 2002May 13, 2008The General Hospital CorporationMultilayer device for tissue engineering
US7416889Apr 27, 2006Aug 26, 2008Rhode Island HospitalMethods and compositions for repairing cartilage
US7468075Nov 27, 2002Dec 23, 2008Conformis, Inc.Methods and compositions for articular repair
US7468192Jul 22, 2003Dec 23, 2008Histogenics CorporationMethod for repair of cartilage lesions
US7479160May 30, 2001Jan 20, 2009Warsaw Orthopedic, Inc.Interbody fusion grafts and instrumentation
US7485310Aug 12, 2004Feb 3, 2009Tigenix N.V.Use of CXCL6 chemokine in the prevention or repair of cartilage defects
US7488348Jun 14, 2005Feb 10, 2009Musculoskeletal Transplant FoundationCartilage allograft plug
US7513910Dec 8, 2004Apr 7, 2009Rti Biologics, Inc.Soft and calcified tissue implants
US7531000Sep 24, 2007May 12, 2009Zimmer, Inc.Cartilage implant
US7537617Jun 5, 2003May 26, 2009Warsaw Orthopedic, Inc.Bone strip implants and method of making same
US7537780Jul 22, 2003May 26, 2009Histogenics CorporationMethod for preparing and implanting a cartilage construct to treat cartilage lesions
US7550007Feb 23, 2007Jun 23, 2009Biomet Sports Medicine, LlcOsteochondral allografts
US7563455Aug 6, 2001Jul 21, 2009Warsaw Orthopedic, Inc.Highly-mineralized osteogenic sponge compositions, and uses thereof
US7563769Nov 5, 2004Jul 21, 2009ProChon Biotech, Ltd.FGF variants and methods for use thereof
US7601173May 7, 2007Oct 13, 2009Synthes Usa, LlcMultipiece allograft implant
US7608113Nov 24, 2003Oct 27, 2009Synthes Usa, LlcDemineralized bone implants
US7621963Apr 11, 2006Nov 24, 2009Ebi, LlcComposite bone graft material
US7622438Jul 12, 2006Nov 24, 2009Acologix, Inc.Protein formulation for promoting hard tissue formation
US7622562Oct 27, 2006Nov 24, 2009Zimmer Orthobiologics, Inc.Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
US7628851May 30, 2008Dec 8, 2009Synthes Usa, LlcBone cement compositions having fiber-reinforcement and/or increased flowability
US7632311Oct 27, 2004Dec 15, 2009Xiros PlcRepair of damaged tissue on a bone site
US7638486Jul 12, 2006Dec 29, 2009Acologix, Inc.Method for promoting hard tissue formation
US7642092Jul 28, 2003Jan 5, 2010Technion Research & Development Foundation Ltd.Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
US7648700Aug 16, 2007Jan 19, 2010Unigene Laboratories, Inc.Method for fostering bone formation and preservation
US7648965Nov 7, 2005Jan 19, 2010Unigene Laboratories Inc.Method for fostering bone formation and preservation
US7658768Oct 15, 2007Feb 9, 2010Wright Medical Technology, Inc.Bone graft substitute composition
US7662184Feb 19, 2007Feb 16, 2010Osteotech, Inc.Osteoimplant and method for making same
US7666230Dec 8, 2003Feb 23, 2010Depuy Products, Inc.Implant device for cartilage regeneration in load bearing articulation regions
US20010005592Jan 16, 2001Jun 28, 2001Bhatnagar Rajendra S.Chondrocyte-like cells useful for tissue engineering and methods
US20010006634Feb 6, 2001Jul 5, 2001The General Hospital CorporationBonding of cartilaginous matrices using isolated chondrocytes
US20010010023Mar 8, 2001Jul 26, 2001Schwartz Robert E.Cartilage repair unit
US20010011131Dec 5, 2000Aug 2, 2001Luyten Frank P.DNA molecules encoding cartilage-derived morphogenetic proteins
US20010016646Mar 20, 1998Aug 23, 2001David C. RuegerOsteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects
US20010018619Jan 22, 2001Aug 30, 2001Robert-Jan EnzerinkGraft material convenience package
US20010020188Feb 5, 2001Sep 6, 2001Tom SanderSelective uptake of materials by bone implants
US20010021875Jan 22, 2001Sep 13, 2001Robert-Jan EnzerinkGraft material convenience package
US20010031254Feb 12, 2001Oct 18, 2001Bianchi John R.Assembled implant
US20010039457Mar 22, 2001Nov 8, 2001Boyer Michael L.Plugs for filling bony defects
US20010039458Mar 22, 2001Nov 8, 2001Boyer Michael L.Implants formed of coupled bone
US20010043940Jul 24, 2001Nov 22, 2001Boyce Todd M.Load-bearing osteoimplant, method for its manufacture and method of repairing bone using same
US20010051834Aug 6, 2001Dec 13, 2001Chondros, Inc.Method for composite cell-based implants
US20020009805Apr 4, 2001Jan 24, 2002Ramot University Authority For Applied Research & Industrial Development Ltd.Scaffold matrix and tissue maintaining systems
US20020016592May 30, 2001Feb 7, 2002Branch Charles L.Interbody fusion grafts and instrumentation
US20020035401Oct 9, 2001Mar 21, 2002Osteotech, Inc.Osteogenic implants derived from bone
US20020042373Jul 19, 2001Apr 11, 2002The Board Of Regents, The University Of Texas SystemStimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
US20020045940May 17, 2001Apr 18, 2002Bruno GiannettiMethods, instruments and materials for chondrocyte cell transplantation
US20020055783May 1, 2001May 9, 2002Tallarida Steven J.System and method for joint resurface repair
US20020072806Aug 29, 2001Jun 13, 2002Dayna BuskirkSoft and calcified tissue implants
US20020082704Feb 28, 2002Jun 27, 2002Cryolife, Inc.Osteochondral transplant techniques
US20020099448May 27, 1999Jul 25, 2002Michael C. HilesMulti-formed collagenous biomaterial medical device
US20020106393Aug 27, 2001Aug 8, 2002Bianchi John R.Assembled implant, including mixed-composition segment
US20020111695Apr 12, 2002Aug 15, 2002Mount Sinai Hospital CorporationReconstituted mineralized cartilage tissue
US20020120274Feb 26, 2001Aug 29, 2002Ethicon, Inc.Tissue scaffold anchor for cartilage repair
US20020138143Jul 16, 2001Sep 26, 2002Grooms Jamie M.Cortical bone cervical Smith-Robinson fusion implant
US20020177224Mar 15, 2001Nov 28, 2002Henning MadryTissue engineering enhanced by the transfer of a growth factor gene
US20020192263May 20, 2002Dec 19, 2002Merboth Barbara L.Allograft bone composition having a gelatin binder
US20030021827Jul 15, 2002Jan 30, 2003Prasanna MalaviyaHybrid biologic/synthetic porous extracellular matrix scaffolds
US20030023316Jun 14, 2002Jan 30, 2003Brown Laura JeanHybrid biologic-synthetic bioabsorable scaffolds
US20030032961Jul 15, 2002Feb 13, 2003Pelo Mark JosephDevices from naturally occurring biologically derived materials
US20030033021Jul 15, 2002Feb 13, 2003Plouhar Pamela LynnCartilage repair and regeneration scaffold and method
US20030033022Jul 15, 2002Feb 13, 2003Plouhar Pamela LynnCartilage repair and regeneration device and method
US20030036797Jul 15, 2002Feb 20, 2003Prasanna MalaviyaMeniscus regeneration device and method
US20030036801Jul 15, 2002Feb 20, 2003Schwartz Herbert E.Cartilage repair apparatus and method
US20030039695Aug 7, 2002Feb 27, 2003Ed. Geistlich Soehne Ag Fuer Chemische IndustrieCollagen carrier of therapeutic genetic material, and method
US20030040113Mar 22, 2002Feb 27, 2003Histogenics CorporationComposition and methods for the production of biological tissues and tissue constructs
US20030044444Jul 15, 2002Mar 6, 2003Prasanna MalaviyaPorous extracellular matrix scaffold and method
US20030049299Jul 15, 2002Mar 13, 2003Prasanna MalaviyaPorous delivery scaffold and method
US20030050709Feb 25, 2002Mar 13, 2003Ulrich NothTrabecular bone-derived human mesenchymal stem cells
US20030055502May 28, 2002Mar 20, 2003Philipp LangMethods and compositions for articular resurfacing
US20030078617Jul 15, 2002Apr 24, 2003Schwartz Herbert E.Unitary surgical device and method
US20030099620Oct 16, 2002May 29, 2003The General Hospital CorporationBonding of cartilaginous matrices using isolated chondrocytes
US20030144743Nov 1, 2002Jul 31, 2003Edwards Jean T.Osteoimplant and method for making same
US20030229400May 12, 2003Dec 11, 2003Koichi MasudaTissue engineered osteochondral implant
US20030236573Jun 13, 2002Dec 25, 2003Evans Douglas G.Devices and methods for treating defects in the tissue of a living being
US20040028717Aug 5, 2003Feb 12, 2004Transtissue Technologies, GmbhImplantable substrates for the healing and protection of connective tissue, preferably cartilage
US20040033212Jul 30, 2001Feb 19, 2004Thomson Brian MarkTissue implant
US20040039447Aug 28, 2003Feb 26, 2004Ultra Tec Manufacturing, Inc.Cartilage repair plug
US20040044408Sep 3, 2003Mar 4, 2004Hungerford David S.Cell-culture and polymer constructs
US20040062753Sep 27, 2002Apr 1, 2004Alireza RezaniaComposite scaffolds seeded with mammalian cells
US20040078090Feb 25, 2003Apr 22, 2004Francois BinetteBiocompatible scaffolds with tissue fragments
US20040102850Nov 25, 2002May 27, 2004Shepard Yolanda DeniseCortical and cancellous allograft spacer
US20040115172Dec 23, 2002Jun 17, 2004Regeneration Technologies, Inc.Assembled implant, including mixed-composition segment
US20040134502Jul 22, 2003Jul 15, 2004Shuichi MizunoMethod for in situ repair of injured, damaged, diseased or aged articular cartilage
US20040138748Dec 29, 2003Jul 15, 2004Synthes (Usa)Plugs for filling bony defects
US20040143344Dec 29, 2003Jul 22, 2004Prasanna MalaviyaImplantable tissue repair device and method
US20040151705Jul 22, 2003Aug 5, 2004Shuichi MizunoNeo-cartilage constructs and a method for preparation thereof
US20040166169Jul 15, 2002Aug 26, 2004Prasanna MalaviyaPorous extracellular matrix scaffold and method
US20040170610Mar 5, 2002Sep 2, 2004Shimon SlavinCompositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation
US20040175826Jul 28, 2003Sep 9, 2004Technion Research & Development Foundation Ltd.Cultured cartilage/bone cells/tissue, method of generating same and uses thereof
US20040192605Feb 18, 2004Sep 30, 2004Genetics Institute, LlcMethods and compositions for healing and repair of articular cartilage
US20040193268Mar 31, 2003Sep 30, 2004Hazebrouck Stephen A.Intercalary prosthesis, kit and method
US20040197311Apr 21, 2004Oct 7, 2004Brekke John H.Device for regeneration of articular cartilage and other tissue
US20040197373Apr 21, 2004Oct 7, 2004Gertzman Arthur A.Composition for filling bone defects
US20040219182Apr 29, 2003Nov 4, 2004Gomes Katherine A.Novel glue for cartilage repair
US20040220574Jul 15, 2002Nov 4, 2004Pelo Mark JosephDevice from naturally occuring biologically derived materials
US20040230303May 16, 2003Nov 18, 2004Gomes Katherine A.Cartilage allograft plug
US20040243242Feb 12, 2002Dec 2, 2004Sybert Daryl R.Implant derived from bone
US20050004672Feb 18, 2004Jan 6, 2005John PaffordBone grafts
US20050020500Jul 22, 2004Jan 27, 2005Bojang ShenNutraceuticals for the treatment, protection and restoration of connective tissues
US20050027307Jul 15, 2002Feb 3, 2005Schwartz Herbert EugeneUnitary surgical device and method
US20050043814Aug 18, 2004Feb 24, 2005Akihiko KusanagiAcellular matrix implanted into an articular cartilage or osteochondral lesion protected with a biodegradable polymer modified to have extended polymerization time and methods for preparation and use thereof
US20050064042Oct 12, 2004Mar 24, 2005Musculoskeletal Transplant FoundationCartilage implant plug with fibrin glue and method for implantation
US20050074476Oct 3, 2003Apr 7, 2005El GendlerCartilidge and bone induction by artificially perforated organic bone matrix augmented by undifferentiated cells suspended in bone gel
US20050074481Sep 8, 2004Apr 7, 2005Brekke John H.Device for regeneration of articular cartilage and other tissue
US20050089544Nov 23, 2004Apr 28, 2005Khouri Roger K.Manufacture of autogenous replacement body parts
US20050101957Dec 8, 2004May 12, 2005Regeneration Technologies, Inc.Soft and calcified tissue implants
US20050112761Nov 1, 2004May 26, 2005Artecel Sciences, Inc.Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair
US20050129668Feb 3, 2005Jun 16, 2005Verigen AgMethods, instruments and materials for chondrocyte cell transplantation
US20050152882Dec 13, 2004Jul 14, 2005Isto TechnologiesParticulate cartilage system
US20050159820May 12, 2003Jul 21, 2005Hideki YoshikawaMember for regenerating joint cartilage and process for producing the same, method of regenerating joint cartilage and artificial cartilage for transplantation
US20050159822Jan 20, 2005Jul 21, 2005Lifecell Corporation, A Delaware CorporationParticulate acellular tissue matrix
US20050196460Mar 8, 2004Sep 8, 2005Malinin Theodore I.Particulate cartilage compositions, processes for their preparation and methods for regenerating cartilage
US20050209705Mar 9, 2005Sep 22, 2005Niederauer Gabriele GImplant scaffold combined with autologous or allogenic tissue
US20050222687Apr 2, 2004Oct 6, 2005Gordana Vunjak-NovakovicCartilage implant assembly and method for implantation
US20050228498Nov 18, 2004Oct 13, 2005Todd AndresOsteoconductive integrated spinal cage and method of making same
US20050240281Aug 31, 2004Oct 27, 2005Slivka Michael AFiber-reinforced, porous, biodegradable implant device
US20050251268Jun 14, 2005Nov 10, 2005Musculoskeletal Transplant FoundationCartilage allograft plug
US20050260612Sep 30, 2004Nov 24, 2005Depuy Spine, Inc.Chemical treatment for removing cellular and nuclear material from naturally occurring extracellular matrix-based biomaterials
US20050261681May 30, 2001Nov 24, 2005Branch Charles LInterbody fusion grafts and instrumentation
US20050261767Sep 30, 2004Nov 24, 2005LifenetComposite bone graft, method of making and using same
US20050288796Jun 23, 2004Dec 29, 2005Hani AwadNative soft tissue matrix for therapeutic applications
US20060030948Sep 21, 2005Feb 9, 2006Albert ManriqueOsteoimplant and method of making same
US20060060209Sep 23, 2004Mar 23, 2006Shepard David OOsteochondral repair using plug fashioned from partial distal allograft femur or condyle
US20060099234Dec 5, 2003May 11, 2006Heinz WinklerImplant containing cultured cartilage cells and method for producing this implant
US20060111778Oct 27, 2005May 25, 2006Michalow Alexander EMethods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
US20060167483Mar 14, 2006Jul 27, 2006Verigen AgMethod, instruments, and kit for autologous transplantation
US20060178748Nov 30, 2005Aug 10, 2006Dinger Fred B IiiImplants and delivery system for treating defects in articulating surfaces
US20060200166Feb 6, 2006Sep 7, 2006Zimmer Spine, Inc.Bone implants and methods
US20060210643Mar 16, 2005Sep 21, 2006Truncale Katherine A GCartilage repair mixture containing allograft chondrocytes
US20060216323Jan 19, 2006Sep 28, 2006David KnaackPolyurethanes for osteoimplants
US20060216822Apr 28, 2006Sep 28, 2006Histogenics CorporationMethod for preparation of neo-cartilage constructs
US20060235534Apr 17, 2006Oct 19, 2006Gertzman Arthur AVertebral disc repair
US20060247790Apr 30, 2005Nov 2, 2006Mckay William FShaped osteochondral grafts and methods of using same
US20060247791Apr 29, 2005Nov 2, 2006Mckay William FMulti-purpose medical implant devices
US20060251631Apr 26, 2006Nov 9, 2006Isto Technologies, Inc.Treatment of joint disease, methods and apparatuses therefor
US20060276907Aug 17, 2006Dec 7, 2006Boyer Michael L IiMultipiece implants formed of bone material
US20070009610Jul 7, 2006Jan 11, 2007Carina SyringEngineered osteochondral construct for treatment of articular cartilage defects
US20070014867Sep 22, 2006Jan 18, 2007Histogenics CorpAcellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof
US20070026030Jul 27, 2005Feb 1, 2007Berkeley Advanced Biomaterials, Inc.Method of preparing rheological materials for bone and cartilage repair
US20070036834Sep 15, 2006Feb 15, 2007Pauletti Giovanni MMethod for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration
US20070041950Feb 1, 2006Feb 22, 2007Osteobiologics, Inc.Method and device for selective addition of a bioactive agent to a multi-phase implant
US20070055377Sep 22, 2006Mar 8, 2007Zimmer Spine, Inc.Bone implants and methods
US20070065943Sep 19, 2006Mar 22, 2007Histogenics Corp.Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US20070067032Jun 25, 2004Mar 22, 2007Felt Jeffrey CMeniscus preserving implant method and apparatus
US20070083266Nov 21, 2006Apr 12, 2007Vertegen, Inc.Devices and methods for treating facet joints, uncovertebral joints, costovertebral joints and other joints
US20070093896Oct 26, 2005Apr 26, 2007Malinin Theodore IMethod and instrumentation for the preparation and transplantation of osteochondral allografts
US20070093912Oct 24, 2006Apr 26, 2007Mark BordenPorous and nonporous materials for tissue grafting and repair
US20070098759Nov 28, 2006May 3, 2007Malinin Theodore IMethod for regenerating cartilage
US20070100045Oct 31, 2006May 3, 2007Kenji KimuraGranule mass
US20070113951Dec 16, 2005May 24, 2007National Tsing Hua UniversityOsteochondral composite scaffold for articular cartilage repair and preparation thereof
US20070128155Dec 7, 2006Jun 7, 2007Isto Technologies, Inc.Cartilage repair methods
US20070134291Nov 7, 2006Jun 14, 2007Kang TingComposition for cartilage
US20070135917Feb 21, 2007Jun 14, 2007Malinin Theodore IInstrumentation for the preparation and transplantation of osteochondral allografts
US20070135918Feb 23, 2007Jun 14, 2007Malinin Theodore IInstrumentation for the preparation and transplantation of osteochondral allografts
US20070135928Feb 23, 2007Jun 14, 2007Malinin Theodore IOsteochondral allografts
US20070148242Feb 23, 2004Jun 28, 2007Zimmer Orthobiologics, IncPreparation for repairing cartilage tissue, especially articular cartilage defects
US20070162121Jan 12, 2007Jul 12, 2007Tarrant Laurence JMethod for repair and reconstruction of ruptured ligaments or tendons and for treatment of ligament and tendon injuries
US20070168030Feb 19, 2007Jul 19, 2007Edwards Jean TOsteoimplant and Method for Making Same
US20070172506Jan 25, 2006Jul 26, 2007Sdgi Holdings, Inc.Osteochondral implant procedure
US20070179601Apr 2, 2007Aug 2, 2007Abbott Laboratories Vascular Enterprises LimitedMethods and apparatus for stenting comprising enhanced embolic protections coupled with improved protections against restenosis and trombus formation
US20070185585Dec 22, 2006Aug 9, 2007Brat BracyImplant Scaffold Combined With Autologous Tissue, Allogenic Tissue, Cultured Tissue, or combinations Thereof
US20070276506May 25, 2006Nov 29, 2007Biomet Manufacturing Corp.Demineralized osteochondral plug
US20070299517Jun 21, 2006Dec 27, 2007Howmedica Osteonics Corp.Articular cartilage implant
US20070299519Sep 4, 2007Dec 27, 2007Reinhold SchmiedingPreformed implants for osteochondral repair
US20080015709Jul 10, 2007Jan 17, 2008Evans Douglas GDevices and methods for treating defects in the tissue of a living being
US20080027546Jul 23, 2007Jan 31, 2008Semler Eric JPacked demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
US20080031915May 20, 2005Feb 7, 2008Jose Becerra RatiaCartilage and Bone Repair Composition
US20080038314Oct 12, 2007Feb 14, 2008Hunziker Ernst BCompositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
US20080039939Aug 2, 2004Feb 14, 2008Yukihide IwamotoMethod of Constructing Artificial Joint
US20080039954Aug 8, 2007Feb 14, 2008Howmedica Osteonics Corp.Expandable cartilage implant
US20080039955Oct 12, 2007Feb 14, 2008Hunziker Ernst BCompositions and methods for the treatment and repair of defects or lesions in articular cartilage using synovial-derived tissue or cells
US20080051889Sep 24, 2007Feb 28, 2008Zimmer, Inc.Cartilage implant
US20080065210Sep 11, 2006Mar 13, 2008Mckay William FMulti-phase osteochondral implantable device
US20080077251Jul 16, 2007Mar 27, 2008Chen Silvia SCleaning and devitalization of cartilage
US20080119947Nov 16, 2007May 22, 2008Smith & Nephew, Inc.Annular Ring Implant
US20080125863Nov 28, 2006May 29, 2008Mckay William FImplant designs and methods of improving cartilage repair
US20080125868Dec 12, 2005May 29, 2008Rickard BranemarkImplant And An Implant Member
US20080138414Dec 6, 2007Jun 12, 2008Smith & Nephew, Inc.Methods of Regenerating Cartilage
US20080153157Dec 20, 2006Jun 26, 2008Zimmer Orthobiologics, Inc.Method of obtaining viable small tissue particles and use for tissue repair
US20080154372Dec 21, 2006Jun 26, 2008Peckham Steven MOsteochondral implant using a growth factor concentration gradient for repair of bone and cartilage tissue
US20080167716Mar 21, 2008Jul 10, 2008Schwartz Hebert ECartilage repair apparatus and method
US20080183300Feb 26, 2008Jul 31, 2008University Of LeedsFixation technology
US20080305145May 30, 2008Dec 11, 2008Bacterin International, Inc.Process for demineralization of bone matrix with preservation of natural growth factors
US20090043389Aug 14, 2008Feb 12, 2009Gordana Vunjak-NovakovicCartilage implant plug with fibrin glue and method for implantation
US20090069901Jul 24, 2008Mar 12, 2009Katherine Gomes TruncaleCartilage allograft plug
US20090069904Sep 12, 2008Mar 12, 2009Applied Medical ResearchBiomaterial including micropores
US20090076624Sep 12, 2008Mar 19, 2009Mohamed Naushad RahamanSynthetic osteochondral composite and method of fabrication thereof
US20090081276Aug 13, 2008Mar 26, 2009Eben AlsbergBioresorbable implant composition
US20090099661Aug 12, 2008Apr 16, 2009Jinia BhattacharyaMultiple component osteoimplant
US20090117652Dec 29, 2008May 7, 2009Tigenix N.V.Use of cxcl6 chemokine in the prevention or repair of cartilage defects
US20090131986Nov 19, 2008May 21, 2009David LeeMethod and apparatus for spinal facet joint fusion using irregularly shaped cortical bone implants
US20090149893Dec 4, 2008Jun 11, 2009Semler Eric JCancellous Bone Implant for Cartilage Repair
US20090210057Apr 20, 2009Aug 20, 2009Chun-Jan LiaoMulti-layered implant prepared by a method of tissue repair using a multi-layered matrix
US20090226523Oct 20, 2008Sep 10, 2009Keyvan BehnamDemineralized bone matrix compositions and methods
US20090280179Feb 9, 2007Nov 12, 2009Hans-Georg NeumannResorbable Calcium Phosphate Based Biopolymer-Cross-Linked Bone Replacement Material
US20090299475Dec 3, 2009Gc CorporationBone graft substitute
US20090312805Dec 22, 2008Dec 17, 2009Conformis, Inc.Methods and compositions for articular repair
US20090312842Jun 16, 2008Dec 17, 2009Predrag BursacAssembled Cartilage Repair Graft
US20090319051Dec 24, 2009Nycz Jeffrey HOsteochondral plug graft, kit and method
US20100021521Jan 8, 2009Jan 28, 2010Guo-Feng XuProsthesis for joint cartilage repair and method of manufacture
US20100036492Feb 11, 2010The Curators Of The University Of MissouriOsteochondral implants, arthroplasty methods, devices, and systems
US20100036503Feb 11, 2010Chen Silvia SComposition for a Tissue Repair Implant and Methods of Making the Same
USRE39321Jun 20, 2003Oct 3, 2006The American National Red CrossSupplemented and unsupplemented tissue sealants, methods of their production and use
EP0517030A2May 19, 1992Dec 9, 1992MAN Ceramics GmbHVertebral implant
EP0517030B1May 19, 1992Sep 4, 1996MAN Ceramics GmbHVertebral implant
EP0522569A1Jul 10, 1992Jan 13, 1993United States Surgical CorporationComposition for effecting bone repair
EP0739631A2Apr 25, 1996Oct 30, 1996El GendlerLaminar bone support for cartilage growth
EP0739631B1Apr 25, 1996Mar 12, 2003Family Limited Partnership GendlerLaminar bone support for cartilage growth
EP0762903A1Jun 2, 1995Mar 19, 1997Creative Biomolecules, Inc.Manufacture of autogenous replacement body parts
EP0762903B1Jun 2, 1995Sep 17, 2003Stryker CorporationManufacture of autogenous replacement body parts
EP0762903B2Jun 2, 1995Aug 22, 2007Stryker CorporationManufacture of autogenous replacement body parts
EP0784985A1Sep 28, 1995Jul 23, 1997Yamanouchi Pharmaceutical Co. Ltd.Osteoplastic graft
EP0968012B1Mar 20, 1998Sep 6, 2006Stryker CorporationOsteogenic devices and methods of use thereof for repair of bone
EP1127581A1Feb 22, 2000Aug 29, 2001Musculoskeletal Transplant FoundationMalleable paste for filling bone defects
EP1127581B1Feb 22, 2000Jun 15, 2005Musculoskeletal Transplant FoundationMalleable paste for filling bone defects
EP1181908A1Aug 29, 1997Feb 27, 2002VTS Holdings, Ltd.Method, instruments and kit for autologous transplantation
EP1181908B1Aug 29, 1997Dec 17, 2003Verigen Transplantation Service International (VTSI) AGSupport for chondrocyte transplantation in cartilage and joint repair
EP1234552A1Feb 25, 2002Aug 28, 2002Ethicon, Inc.Scaffold fixation device for use in articular cartilage repair
EP1234552B1Feb 25, 2002Aug 16, 2006Ethicon, Inc.Scaffold fixation device for use in articular cartilage repair
EP1234555A2Feb 25, 2002Aug 28, 2002Ethicon, Inc.Tissue scaffold anchor for cartilage repair
EP1234555A3Feb 25, 2002Jun 16, 2004Ethicon, Inc.Tissue scaffold anchor for cartilage repair
EP1234555B1Feb 25, 2002Feb 7, 2007Ethicon, Inc.Tissue scaffold anchor for cartilage repair
EP1237511A1Dec 12, 2000Sep 11, 2002Sulzer Orthopedics Ltd.Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
EP1237511B1Dec 12, 2000Sep 1, 2004Sulzer Orthopedics Ltd.Preparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
EP1384452A1Aug 29, 1997Jan 28, 2004Verigen Transplantation Service International (VTSI) AGMethod, instruments and kit for autologous transplantation
EP1537883B1Dec 3, 2004Apr 23, 2008DePuy Mitek, Inc.Implants comprising viable tissue for repairing a tissue injury or defect
EP1561481A2Feb 8, 2005Aug 10, 2005DePuy Mitek, Inc.Scaffolds with viable tissue
EP1618178B1Apr 21, 2004Jul 16, 2008Musculoskeletal Transplant FoundationNovel glue for cartilage repair
EP1719463A1Dec 4, 2000Nov 8, 2006University Of LeedsRepair of damaged tissue
EP1719531A2Mar 20, 1998Nov 8, 2006Stryker CorporationOsteogenic devices and methods of use thereof for repair of bones
EP1719532A2Mar 20, 1998Nov 8, 2006Stryker CorporationOsteogenic devices and methods of use thereof for repair of bones
GB2102811B Title not available
SU1454423A1 Title not available
WO02/077199A2 Title not available
WO02/095019A1 Title not available
WO03/007873A2 Title not available
WO03/012053A2 Title not available
WO03/079985A2 Title not available
WO03/087160A1 Title not available
WO03/094835A2 Title not available
WO03/094835A3 Title not available
WO2000/47114A1 Title not available
WO2001/07595A2 Title not available
WO2001/38357A2 Title not available
WO2001/39788A2 Title not available
WO2001/46416A1 Title not available
WO2002/18546A2 Title not available
WO2002/22779A2 Title not available
WO2002/36732A2 Title not available
WO2002/36732A3 Title not available
WO2002/95019A1 Title not available
WO2090/01342A1 Title not available
WO2093/16739A1 Title not available
WO2095/24310A1 Title not available
WO2095/25748A1 Title not available
WO2098/43686A1 Title not available
WO2099/15209A1 Title not available
WO2099/56797A1 Title not available
WO1984004880A1May 24, 1984Dec 20, 1984University Patents IncBody implants of extracellular matrix and means and methods of making and using such implants
WO1994003584A1Aug 5, 1993Feb 17, 1994Tissue Eng IncProduction of graft tissue from extracellular matrix
WO1995033502A1Jun 2, 1995Dec 14, 1995Creative Biomolecules IncManufacture of autogenous replacement body parts
WO1998014222A1Sep 29, 1997Apr 9, 1998Childrens Medical CenterMethods and compositions for programming an organic matrix for remodeling into a target tissue
WO1998041246A2Mar 20, 1998Sep 24, 1998Creative Biomolecules IncOsteogenic devices and methods of use thereof for repair of bone
WO1999009914A1Aug 27, 1998Mar 4, 1999Kevin C CarterCortical bone cervical smith-robinson fusion implant
WO1999011298A2Sep 1, 1998Mar 11, 1999Gensci Regeneration Lab IncReverse phase connective tissue repair composition
WO1999021497A1Oct 7, 1998May 6, 1999Emanuel GautierMethod and instruments for repairing endochondral and osteochondral defects
WO1999048541A1Mar 26, 1999Sep 30, 1999Univ Carnegie MellonAssembled scaffolds for three-dimensional cell culturing and tissue generation
WO1999052572A1Apr 8, 1999Oct 21, 1999Childrens Medical CenterMethods and compositions for tissue regeneration
WO2000040177A1Dec 18, 1999Jul 13, 2000LifenetComposite bone graft, method of making and using same
WO2001043667A1Dec 12, 2000Jun 21, 2001Margarete AkensPreparation for repairing cartilage defects or cartilage/bone defects in human or animal joints
WO2002058484A2Jan 16, 2002Aug 1, 2002Collagen Ii Nutrition IncKolla 2-desiccated avian sternal cartilage powder
WO2002064180A1Sep 7, 2001Aug 22, 2002Regeneration Tech IncAssembled implant, including mixed-composition segment
WO2003007805A2Jul 15, 2002Jan 30, 2003Depuy Products IncCartilage repair apparatus and method
WO2003007805A3Jul 15, 2002Feb 12, 2004Depuy Products IncCartilage repair apparatus and method
WO2003007879A2Jul 15, 2002Jan 30, 2003Depuy Products IncCartilage repair and regeneration scaffold and method
WO2003007879A3Jul 15, 2002Aug 28, 2003Depuy Products IncCartilage repair and regeneration scaffold and method
WO2004067704A2Jan 29, 2004Aug 12, 2004Prochon Biotech LtdFreeze-dried fibrin matrices and methods for preparation thereof
WO2004069298A1Feb 6, 2004Aug 19, 2004Jean-Francois ArnalFgf-2 derived proteins for the preparation of biomaterials or medical devices such as stents
WO2004075940A1Feb 23, 2004Sep 10, 2004Ct Pulse Biolog IncPreparation for repairing cartilage tissue, especially articular cartilage defects
WO2004096983A2Apr 21, 2004Nov 11, 2004Musculoskeletal TransplantNovel glue for cartilage repair
WO2004096983A3Apr 21, 2004Dec 22, 2005Musculoskeletal TransplantNovel glue for cartilage repair
WO2004103224A1Apr 21, 2004Dec 2, 2004Arthur A GertzmanCartilage allograft plug
WO2005058207A1Dec 13, 2004Jun 30, 2005Isto Technologies IncParticulate cartilage system
WO2005110278A2Mar 16, 2005Nov 24, 2005Musculoskeletal TransplantCartilage repair mixture containing allograft chondrocytes
WO2005110278A3Mar 16, 2005Aug 10, 2006Musculoskeletal TransplantCartilage repair mixture containing allograft chondrocytes
WO2006042311A2Oct 12, 2005Apr 20, 2006Musculoskeletal TransplantCartilage implant plug with fibrin glue and method for implantation
WO2006042311A3Oct 12, 2005Nov 23, 2006Musculoskeletal TransplantCartilage implant plug with fibrin glue and method for implantation
WO2006050213A2Oct 27, 2005May 11, 2006Alexander E MichalowMethods of promoting healing of cartilage defects and method of causing stem cells to differentiate by the articular chondrocyte pathway
WO2006113586A2Apr 17, 2006Oct 26, 2006Musculoskeletal TransplantVertebral disc repair
WO2006113586A3Apr 17, 2006Sep 20, 2007Musculoskeletal TransplantVertebral disc repair
WO2007024238A1Aug 26, 2005Mar 1, 2007Massachusetts Inst TechnologyCartilage implant assembly and method for implantation
WO2008013763A2Jul 23, 2007Jan 31, 2008Morris L JacobsPacked demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
WO2008013763A3Jul 23, 2007Jun 26, 2008Morris L JacobsPacked demineralized cancellous tissue forms for disc nucleus augmentation, restoration, or replacement and methods of implantation
WO2008021127A2Aug 8, 2007Feb 21, 2008Howmedica Osteonics CorpExpandable cartilage implant
WO2008038287A2Oct 7, 2007Apr 3, 2008Prochon Biotech LtdN-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008038287A3Oct 7, 2007Apr 23, 2009Hepacore LtdN-terminal fgf variants having increased receptor selectivity and uses thereof
WO2008081463A2Jan 6, 2008Jul 10, 2008Fibron LtdWater soluble reactive derivatives of carboxy polysaccharides and fibrinogen conjugates thereof
WO2008106254A2Jan 23, 2008Sep 4, 2008Musculoskeletal TransplantTwo piece cancellous construct for cartilage repair
WO2009076164A2Dec 4, 2008Jun 18, 2009Musculoskeletal TransplantCancellous bone implant for cartilage repair
Non-Patent Citations
Reference
1"Young's Modulus," Entry on http://en.wikipedia.org. accessed Oct. 27, 2005. 3 pages.
2 *(No Author)"Lyophilization" TechnoBusinesss-Solutions. (No publication date). Retrieved Jul. 1, 2009 from URL: <http://www.technobusiness-solutions.com/article-lyophilization1.html> 10 pages.
3 *(No Author)"Lyophilization" TechnoBusinesss-Solutions. (No publication date). Retrieved Jul. 1, 2009 from URL: 10 pages.
4A final Office Action mailed on Nov. 13, 2008 in connection with U.S. Appl. No. 10/815,778.
5A final Office Action mailed on Sep. 19, 2008 in connection with U.S. Appl. No. 11/081,103.
6A non-final Office Action mailed on Jul. 2, 2009 in connection with U.S. Appl. No. 10/815,778.
7A non-final Office Action mailed on Jul. 9, 2008 in connection with U.S. Appl. No. 11/151,270.
8A non-final Office Action mailed on Jun. 8, 2009 in connection with U.S. Appl. No. 11/481,955.
9A non-final Office Action mailed on May 18, 2009 in connection with U.S. Appl. No. 11/657,042.
10A Written Opinion issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2008/085522.
11A Written Opinion issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2009/001459.
12A Written Opinion issued on Jun. 23, 2009 in connection with International Patent Application No. PCT/US2008/051796.
13Abraham, Judith A. et al., (1986) Human Basic Fibroblast Growth Factor: Nucleotide Sequence And Genomic Organization. EMBO Journal 5(10):2523-2528.
14Advisory Action mailed on Dec. 27, 2007 in connection with U.S. Appl. No. 11/151,270.
15Agrawal, Sudhir et al., (1991) Pharmacokinetics. Biodistribution, And Stability Of Oligodeoxynucleotide Phosphorothioates In Mice. Proc Natl Acad Sci. USA 88(17):7595-7599.
16An International Preliminary Report on Patentability issued on Jul. 28, 2009 in connection with International Patent Application No. PCT/US2008/051796.
17An International Search Report issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2008/085522.
18An International Search Report issued on Jul. 6, 2009 in connection with International Patent Application No. PCT/US2009/001459.
19An International Search Report issued on Jun. 23, 2009 in connection with International Patent Application No. PCT/US2008/051796.
20Andrés et al., "A Pro-Inflammatory Signature Mediates FGF2-induced Angiogenesis", Journal of Cellular and Molecular Medicine, (2008).
21Arakawa, Tsutomu et al., (1993) Production and Characterization of an Analog of Acidic Fibroblast Growth Factor With Enhanced Stability and Biological Activity. Protein Engineering 6(5):541-546.
22Atala et al., Injectable alginate seeded with chondrocytes as a potential treatment for vesicoureteral reflux, J. of Urology 150(2 Pt 2):745-7 (1993).
23Aviles et al., "Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2)", British Journal of Pharmacology (2003) 140: 637-646.
24Bailly, Karine et al., (2000) Uncoupling of cell proliferation and differentiation activities of basic fibroblast growth factor. FASEB Journal 14(2):333-343.
25Baird, "Fibroblast growth factors: activities and significance of non-neurotrophin neurotrophic growth factors", Current Opinions in Neurobiology, (1994) 4:78-86.
26Bange, Johannes et al., (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 Allele. Cancer Research 62(3):840-846.
27Bork, Peer (2000) Powers and pitfalls in sequence analysis: The 70% hurdle. Genome Res. 10(4):398-400.
28Bork, Peer and Bairoch, Amnon (1996) Go hunting in sequence databases but watch out for the traps. Trends in Genetics 12(10):425-427.
29Bradford, Marion M. (1976) A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Analytical Biochemistry 72(1-2):248-254.
30Breinan et al., "Autologous Chondrocyte Implantation in a Canine Model: Change in Composition of Reparative Tissue with Time", Journal of Orthopaedic Research, 2001; 19:482-492.
31Breinan et al., "Effect of Cultured Autologous Chondrocytes on Repair of Chondral Defects in a Canine Model", Journal of Bone and Joint Surgery [Am], Oct. 1997; vol. 79-A, No. 10, 1439-1451.
32Brenner, Steven E. (1999) Errors in genome annotation. Trends in Genetics 15(4):132-133.
33Brighton et al., "Articular Cartilage Preservation and Storage-I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage", Arthritis and Rheumatism, vol. 22, No. 10 (Oct. 1979) pp. 1093-1101.
34Brighton et al., "Articular Cartilage Preservation and Storage—I. Application of Tissue Culture Techniques to the Storage of Viable Articular Cartilage", Arthritis and Rheumatism, vol. 22, No. 10 (Oct. 1979) pp. 1093-1101.
35Brittberg et al., "Autologous Chondrocytes Used for Articular Cartilage Repair: An Update", Clinical Orthopaedics and Related Research, 2001; No. 391 Suppl: S337-S348.
36Brittberg et al., "Rabbit Articular Cartilage Defects Treated with Autologous Cultured Chondrocytes", Clinical Orthopaedics and Related Research, 1996; 326:270-283.
37Brittberg et al., "Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation", New England Journal of Medicine, Oct. 6, 1994, vol. 331, No. 14, pp. 889-895.
38Buckwalter et al., "Articular Cartilage: Degeneration and Osteoarthritis, Repair, Regeneration, and Transplantation", AAOS Instructional Course Lectures, 1998; 47:487-504.
39Buckwalter, "Articular Cartilage Injuries", Clinical Orthopaedics and Related Research, 2002, No. 402, pp. 21-37.
40Bugbee, "Fresh Osteochondral Allografting", Operative Techniques in Sports Medicine, Apr. 2000, vol. 8, No. 2, pp. 158-162.
41Burger et al., "Fibroblast growth factor receptor-1 is expressed by endothelial progenitor cells", Blood, vol. 100, No. 10 (Nov. 15, 2002) 3527-35.
42Bursac, "Collagen Network Contributions to Structure-Function Relationships in Cartilaginous Tissues in Compression" (Dissertation), Boston University College of Engineering, 2002.
43Canadian Office Action issued on Aug. 24, 2009 in connection with Canadian Patent Application No. 2,563,082.
44Cappellen, David et al., (1999) Frequent activating mutations of FGFR3 In human bladder arid cervix carcinomas. Nature Genetics 23(1):18-20.
45Carr, M. E. Jr. and Alving, B. M. (1995) Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag, Fibrinol. 6(6):567-573.
46Carr, Marcus E. (1998) Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb. Haemost. 59(3):535-539.
47Chen et al., "Repair of Articular Cartilage Defects: Part I. Basic Science of Cartilage Healing", The American Journal of Orthopedics, Jan. 1999, pp. 31-33.
48Chen et al., "Repair of Articular Cartilage Defects: Part II. Treatment Options", The American Journal of Orthopedics, Feb. 1999, pp. 88-96.
49Chusho, Hideki et al., (2001) Dwarfism and earlydeath in mice lacking C-type Natriuretic Peptide. Proc Natl Acad Sci. 98(7):4016-4021.
50Cook, James L. et al., (2003) Biocompatibility of three-dimensional chondrocyte grafts in large tibial defects of rabbits. Am J Vet Res. 64(1):12-20.
51Coughlin, Shaun R. et al., (1988) Acidic and basic fibroblast growth factors stimulate tyrosine kinase activity in vivo. J Biol Chem. 263(2):988-993.
52Crescenzi et al., "Hyaluronan Linear and Crosslinked Derivatives as Potential/Actual Biomaterials", in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 261-268.
53Dahlberg et al., "Demineralized Allogeneic Bone Matrix for Cartilage Repair", Journal of Orthopaedic Research, 1991, vol. 9, pp. 11-19.
54Dell'Accio, Francesco et al., (2001) Molecular markers predictive of the capacity of expanded human articular chondrocytes to form stable cartilage in vivo, Arthritis Rheum. 44(7):1608-19.
55Diduch et al., "Joint Repair: Treatment Options for Articular Cartilage Injury" Orthopedic Technology Review (2002) 4:24-27.
56Doerks, Tobias et al., (1998) Protein annotation: detective work for function prediction. Trends Genet. 14(6):248-250.
57Dvorakova, Dana et al., (2001) Changes in the expression of FGFR3 in patients with chronic myeloid leukaemia receiving transplant of allogeneic peripheral blood stem cells_British Journal Haematology 13(3):832-835.
58Eriksson, A. Elisabeth et al., (1991) Three-dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA 88:3441-3445 (XP002936511).
59Ezzat Shereen et al., (2002) Targeted expression of A Human pituitary tumor-derived isoform of FGF Receptor-4 Recapitulates Pituitary Tumorigenesis. Journal of Clinical Investigation 109(1):69-77.
60Faham, Salem et al., (1998) Diversity does make a difference: fibroblast growth factor—Heparin Interactions. Curr Opin Struct Biol 8(5):578-586.
61Feczko et al., "Experimental Results of Donor Site Filling for Autologous Osteochondral Mosaicplasty", Arthroscopy: The Journal of Arthroscopic and Related Surgery, vol. 19, No. 7 (Sep. 2003), pp. 755-761.
62Final Office Action for U.S. Appl. No. 11/081,103, mailed Aug. 11, 2010.
63Final Office Action for U.S. Appl. No. 11/481,955, mailed Jan. 7, 2010.
64Final Office Action mailed Mar. 15, 2010 in connection with U.S. Appl. No. 10/815,778.
65Final Office Action mailed Mar. 22, 2010 in connection with U.S. Appl. No. 12/010,984.
66Final Office Action mailed on Oct. 18, 2005 in connection with U.S. Appl. No. 10/438,883.
67Final Office Action mailed on Oct. 9, 2007 in connection with U.S. Appl. No. 11/151,270.
68Final Office Action mailed on Sep. 28, 2007 in connection with U.S. Appl. No. 10/960,960.
69Fingl, Edward and Woodbury, Dixon M.(1975) Chapter I: General Priciples; In: The Pharmacological Basis of Therapeutics. Fifth edition. Goodman, Louis S. and Gilman, Alfred editors. 1:1-45.
70Fujisato et al., (1996) Effect of basic fibroblast growth factor on cartilage regeneration in chondrocyte-seeded collagen sponge scaffold. Biomaterials, vol. 17, No. 2, pp. 155-162.
71Gao, Jizong et al., (2002) Repair of osteochondral defect with tissue-engineered two-phase composite material of injectable calcium phosphate and hyaluronan sponge. Tissue Engin. Part A 8(5):827-837.
72Gargiulo, B. J. et al., (2002) Phenotypic modulation of human articular chondrocytes by bistratene A. Eur Cell Mater. 3:9-18.
73Gertzman et al., "A pilot study evaluating sodium hyaluronate as a carrier for freeze-dried demineralized bone powder", Cell and Tissue Banking, vol. 2, 2001, pp. 87-94.
74Gilbert, et al., "Decellularization of Tissue and Organs", Biomaterials (2006) 27:3675-3683.
75Girotto et al., "Tissue-specific gene expression in chondrocytes grown on three-dimensional hyaluronic acid scaffolds", Biomaterials, vol. 24 (2003), pp. 3265-3275.
76Givol, David and Yayon, Avner (1992) Complexity of FGF receptors: genetic basis for structural diversity and functional specificity FASEB J. 6(15):3362-3369.
77Glowacki, "Engineered Cartilage, Bone, Joints and Menisci-Potential for Temporomandibular Joint Reconstruction", Cells Tissues Organs, vol. 169, Issue 3, 2001, pp. 302-308.
78Glowacki, "Engineered Cartilage, Bone, Joints and Menisci—Potential for Temporomandibular Joint Reconstruction", Cells Tissues Organs, vol. 169, Issue 3, 2001, pp. 302-308.
79Gooch et al., "IGF-I and Mechanical Environment Interact to Modulate Engineered Cartilage Development", Biochemical and Biophysical Research Communications, 2001; 286:909-915.
80Gruber, Reinhard et al., (2002) Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res. 13(5):529-535.
81Haisch, A. et al., (2000) Preparation of a pure autologous biodegradable fibrin matrix for tissue engineering. Med Biol Eng Comput. 38(6):686-689.
82Hecht, H. J. et al., (2000) Structure of fibroblast growth factor 9 shows a symmetric dimer with unique receptor-and heparin-binding interfaces. Acta Cryst. D57:378-384.
83Hoffman, "Hydrogels for Biomedical Applications", Advanced Drug Delivery Reviews, 2002, vol. 43, pp. 3-12.
84http://www.stoneclinic.com/articularcartilagepastegrafting, no date.
85http://www.technobusiness-solutions.com/article-lyophilization1.html, published Feb. 12, 2002.
86Hunziker, "Articular cartilage repair: are the intrinsic biological constraints undermining this processiInsuperable?", Osteoarthritis and Cartilage 7 (1999) pp. 15-28.
87Hunziker, "Articular Cartilage Repair: Basic Science and Clinical Progress. A Review of the Current Status and Prospects", Osteoarthritis and Cartilage 2001, vol. 10, No. 6, pp. 432-463.
88Hunziker, "Articular Cartilage Structure in Humans and Experimental Animals", Articular Cartilage and Osteoarthritis, Raven Press, ed., 1992, pp. 183-199.
89International Cartilage Repair Society, "Cartilage Injury Evaluation Package", www.cartilage.org, 2000.
90International Patent Application No. PCT/US2008/051796 filed Jan. 23, 2008 titled Two Piece Cancellous Construct for Cartilage Repair.
91International Patent Application No. PCT/US2009/000108, filed Jan. 14, 2010, entitled "Cartilage Particle Tissue Mixtures Optionally Combined With a Cancellous Construct".
92International Preliminary Report on Patentability for PCT/US2008/085522, mailed on Jun. 17, 2010.
93International Preliminary Report on Patentability for PCT/US2009/001459, mailed on May 12, 2010.
94International Preliminary Report on Patentability issued in connection with International Patent Application No. PCT/US2005/008798 on Nov. 1, 2006.
95International Preliminary Report on Patentability issued on Apr. 17, 2007 2006 in connection with International Patent Application No. PCT/US2005/036878.
96International Preliminary Report on Patentability issued on Feb. 26, 2008 in connection with International Patent Application No. PCT/US2005/030610.
97International Preliminary Report on Patentability issued on Nov. 18, 2005 in connection with International Patent Application No. PCT/US2004/010956.
98International Preliminary Report on Patentability issued on Nov. 18, 2005 in connection with International Patent Application No. PCT/US2004/010957.
99International Search Report and Written Opinion for PCT/US2010/000108, mailed Aug. 24, 2010.
100International Search Report issued in connection with International Patent Application No. PCT/US2004/010956 on Oct. 28, 2005.
101International Search Report issued in connection with International Patent Application No. PCT/US2004/010957 Application on Nov. 1, 2004.
102International Search Report issued in connection with International Patent Application No. PCT/US2005/008798 on Jun. 19, 2006.
103International Search Report issued in connection with International Patent Application No. PCT/US2005/030610 on Apr. 7, 2006.
104International Search Report issued on Sep. 21, 2006 in connection with International Patent Application No. PCT/US2005/036878.
105Itokazu, M. et al., (1997) The sustained release of antibiotic from freeze-dried fibrin-antibioticcompound and efficacies in a rat model of osteomyelitis. Infection 25(6):359-363.
106Jackson et al., "Cartilage Substitutes: Overview of Basic Science & Treatment Options", Journal of American Academy of Orthopaedic Surgeons, vol. 9, Jan./Feb. 2001, pp. 37-52.
107Johnson, Daniel E. and Williams, Lewis T. (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res. 60:1-41.
108Kato et al., "Fibroblast Growth Factor is an Inhibitor of Chondrocyte Terminal Defferentiation", Journal of Biological Chemistry, vol. 265, No. 10 (Apr. 5, 1990) pp. 5903-5909.
109Kirikoshi, Hiroyuki et al., (2000) Molecular cloning and characterization of Human FGF-20 on chromosome 8p21.3-p22. Biochem Biophys Res Commun. 274(2):337-343.
110Kuroda, S. et al., (1999) Anabolic effect of aminoterminally truncated Fibroblast Growth Factor 4 (FGF4) on bone. Bone 25:(4):431-437.
111Loeser et al., "Basic Fibroblast Growth Factor Inhibits the Anabolic of Insulin-like Growth Factor 1 and Osteogenic Protein 1 in Adult Human Articular Chondrocytes", Arthritis & Rheumatism, vol. 52, No. 12 (Dec. 2005), pp. 3910-3917.
112Lu et al., "Minced Cartilage without Cell Culture Serves as an Effective Intraoperative Cell Source for Cartilage Repair", Journal of Orthopaedic Research, Jun. 2006, vol. 24, pp. 1261-1270.
113Madry et al., "Gene Transfer of a Human Insulin-like Growth Factor I cDNA Enhances Tissue Engineering of Cartilage", Human Gene Therapy, 13: 1621-1630 (Sep. 1, 2002).
114Mahadev et al., "Autogenous Osteochondral Morselised Grafts for Full Thickness Osteochondral Defects in the Knee Joints of Pigs", Singapore Medical Journal, 2001, vol. 42(9), pp. 410-416.
115Matsuda et al. (1995) In Vivo Chondrogenesis in Collagen Sponge Sandwiched by Perichondrium. J. Biomater. Sci. Polymer Ed., vol. 7, No. 3, pp. 221-229.
116Mazué et al., "Preclinical and Clinical Studies with Recombinant Human Basic Fibroblast Growth Factor", Annals New York Academy of Sciences, (1991) 329-340.
117Messner et al., "Cartilage Repair: A Critical Review", Acta Orthopaedic Scandinavica, 1996, vol. 67, No. 5, pp. 523-529.
118Messner et al., "The Long-term Prognosis for Severe Damage to Weight-bearing Cartilage in the Knee: A 14-year Clinical and Radiographic Follow-up in 28 Young Athletes", Acta Orthopaedic Scandinavica, 1996, vol. 67, No. 2, pp. 165-168.
119Michielen et al., "Novel Biomaterials Based on Cross-linked Hyaluronan: Structural Investigations", in Hyaluronan (2002), vol. 1 (Chemical, Biochemical and Biological Aspects), J. F. Kennedy et al., Ed., pp. 269-276.
120Nakatake, Yuhki et al., (2001) Identification of a novel fibroblast growth factor. FGF-22, preferentially expressed in the inner root sheath of the hair follicle. Biochim Biophys Acta. 1517(3):460-463.
121Nehrer et al., "Chondrocyte-seeded Collagen Matrices Implanted in a Chondral Defect in a Canine Model", Biomaterials, 1998; 19:2313-2328.
122Nettles et al. (Mar. 2004), "In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair", 50th Annual Meeting of the Orthopaedic Research Society, Paper No. 0202.
123Nettles et al., "In Situ Crosslinkable Hyaluronan For Articular Cartilage Repair", 50th Annual Meeting of the Orthopaedic Research Society, (Mar. 2004) Paper No. 0202.
124Nettles et al., "Photocrosslinkable Hyaluronan As a Scaffold for Articular Cartilage Repair", Annals of Biomedical Engineering, vol. 32, No. 3, Mar. 2004, pp. 391-397.
125Newman, "Articular Cartilage Repair", American Journal of Sports Medicine, 1998, vol. 26, No. 2, pp. 309-324.
126Ngo, J. Thomas et al., (1994) Computational complexity, protein structure prediction, and the Levithal Paradox. In: The Protein Folding Problem and Tertiary Structure Prediction. K. Merz Jr. and S. Le Grand, Editors. 433-506.
127Nishimura, Tetsuya et al., (2000) Identification Of a Novel FGF, FGF-21, Preferentially Expressed In The Liver. Biochim Biophys Acta 1492(1):203-206.
128Nixon et al., "Enhanced Repair of Extensive Articular Defects by Insulin-like Growth Factor-I-Laden Fibrin Composites", Journal of Orthopaedic Research, 1999; 17:475-487.
129Nixon et al., "New Horizons in Articular Cartilage Repair", Proceedings of the Annual Convention of the AAEP, 2001, vol. 47, pp. 217-226.
130Nolan et al., "Living Bone Grafts", BMJ, vol. 304, Jun. 13, 1992, pp. 1520 and 1521.
131Non-Final Office Action for U.S. Appl. No. 11/081,103, mailed Jan. 14, 2010.
132Non-final Office Action for U.S. Appl. No. 12/010,984, mailed Aug. 16, 2010.
133Non-Final Office Action mailed Apr. 12, 2010 in connection with U.S. Appl. No. 12/191,490.
134Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 11/657,042.
135Non-Final Office Action mailed Apr. 15, 2010 in connection with U.S. Appl. No. 12/079,629.
136Non-final Office Action mailed on Apr. 19, 2007 in connection with U.S. Appl. No. 11/151,270.
137Non-final Office Action mailed on Dec. 18, 2007 in connection with U.S. Appl. No. 11/081,103.
138Non-final Office Action mailed on Feb. 20, 2007 in connection with U.S. Appl. No. 10/960,960.
139Non-final Office Action mailed on Feb. 6, 2007 in connection with U.S. Appl. No. 10/438,883.
140Non-final Office Action mailed on Jul. 22, 2009 in connection with U.S. Appl. No. 12/010,984.
141Non-final Office Action mailed on Jun. 3, 2009 in connection with U.S. Appl. No. 11/081,103.
142Non-final Office Action mailed on May 3, 2005 in connection with U.S. Appl. No. 10/438,883.
143Non-final Office Action mailed on Nov. 5, 2004 in connection with U.S. Appl. No. 10/438,883.
144Obradovic et al., "Integration of Engineered Cartilage", Journal of Orthopaedic Research, 19:1089-1097, 2001.
145Office Action dated Jan. 14, 2010, received in U.S. Appl. No. 11/081,103, filed on Mar. 16, 2005.
146Office Action issued on Apr. 24, 2007 in connection with Australian Patent Application No. 2004235291.
147Office Action issued on Nov. 7, 2007 in connection with New Zealand Patent Application No. 543665.
148Office Action issued on Sep. 8, 2006 in connection with European Patent Application No. 04749924.9.
149Office Action mailed Feb. 7, 2008 in connection with U.S. Appl. No. 10/815,778.
150Okada-Ban, Mai et al., (2000) Fibroblast growth factor-2. International Journal of Biochemistry & Cell Biology 32 (3):263-267.
151Olsen, Shaun K. (2003) Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs J. Biol Chem. 278(36); pp. 34226-34236.
152Ornits et al., "Protein Family Review: Fibroblast Growth Factors", Genome Biology (2001) 2(3): reviews 3005.1-3005.12, http://genomebiology.com/2001/2/3/reviews/3005.1.
153Ornitz, David M. (2000) FGFs, heparan sulfate and FGFRs: Complex interactions essential for development. Bio Essays 22:108-112.
154Ornitz, David M. et al., (1996) Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271(25)15292-7.
155Osteo Sponge product information, Bacterin International Inc., May 2005.
156Pearson et al. (eds.), American Association of Tissue Banks, Standards for Tissue Banking, 2008 (12th ed.), pp. 53-56, 86-88.
157Pei et al., "Bioreactors Mediate the Effectiveness of Tissue Engineering Scaffolds", The FASEB Journal, 16:1691-1694, published online (Aug. 7, 2002), 10.1096/fj.02-0083fje.
158Pei et al., "Growth Factors for Sequential Cellular De- and Re-differentiation in Tissue Engineering", Biochemical and Biophysical Research Comunications, 2002; 294:149-154.
159Pellegrini, Luca et al., (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407(6807):1029-1034.
160Peretti et al., "A Biomechanical Analysis of a Chondrocyte-Based Repair Model of Articular Cartilage", Tissue Engineering, Aug. 1, 1999, vol. 5, No. 4, pp. 317-326.
161Peretti et al., "A Biomechanical Analysis of an Engineered Cell-Scaffold Implant for Cartilage Repair", Annals of Plastic Surgery, 2001, vol. 46, No. 5, pp. 533-537.
162Peretti et al., "Bonding of Cartilage Matrices with Cultured Chondrocytes: An Experimental Model", Journal of Orthopedic Research, Jan. 1998, vol. 16, No. 1, pp. 89-95.
163Peretti et al., "Cell-Based Bonding of Articular Cartilage: An Extended Study", Journal of Biomedical Materials Research, 64A, 2003, pp. 517-524.
164Peretti et al., "Cell-Based Tissue-Engineered Allogeneic Implant for Cartilage Repair", Tissue Engineering, 2000, vol. 6, No. 5, pp. 567-576.
165Peretti et al., "In Vitro Bonding of Pre-seeded Chondrocytes", Sport Sciences for Health, May 1, 2007, vol. 2, No. 1, pp. 29-33.
166Peterson et al., "Autologous Chondrocyte Transplantation: Biomechanics and Long-term Durability", American Journal of Sports Medicine, 2002, vol. 30, No. 1, pp. 2-12.
167Peterson et al., "Two- to 9-year Outcome After Autologous Chondrocyte Transplantation of the Knee", Clinical Orthopaedic and Related Research, 2000; No. 374: 212-234.
168Pillai, Omathanu and Panchagnula, Ramesh (2001) Polymers in drug delivery. Curr Opin Chem Biol 5 (4):447-451.
169Plotnikov, Alexander N. et al., (1999) Structural basis for FGF receptor dimerization and activation. Cell 98 (5):641-650.
170Plotnikov, Alexander N. et al., (2000) Crystal structures of two FGF-FGFR complexes reveal the determinants of ligand-receptor specificity. Cell 101(4):413-424.
171Richardson et al., "Repair of Human Articular Cartilage After Implantation of Autologous Chondrocytes", Journal of Bone and Joint Surgery [Br], 1999, 81-B:1064-1068.
172Sahni, Malika et al., (1999) FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes Dev. 13:1361-1366.
173Schaefer et al., "Tissue Engineered Composites for tha Repair of Large Osteochondral Defects", Arthritis & Rheumatism, 46(9): 2524-2534 (2002).
174Schlessinger, Joseph et al., (2000) Crystal structure of a ternary FGF-FGFR-1 Heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6(3):743-750.
175Schmal, H. et al., (2007) bFGF influences human articular chondrocytes differentiation. Cytotherapy 9(2):184-93.
176Seno, Masaharu et al., (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for Heparin. Eur J Biochem. 188:239-245.
177Shano; Zhang-Qiang et al., (2006) Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodelling in a rat infarct model. Circ. J. 70(4):471-477.
178Sims, C. Derek et al., (1998) Tissue engineered neocartilage using plasma derived polymer substrates and chondrocytes. Plastic & Recon. Surg. 101(6):1580-1585.
179Skolnik, Jeffrey and Fetrow, Jacquelyn S. (2000) From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends Bio Technol. 18(1):34-39.
180Sleeman, Matthew et al., (2001) Identification of a new fibroblast growth factor receptor, FGFR5. Gene 271 (2):171-182.
181Smith, Temple and Zhang, Xiaolin (1997) The challenges of genome sequence annotation or The devil is in the details, Nat Biotecehnol. 15(12):1222-1223.
182Springer, Barry A. et al., (1994) Identification and Concerted Function of Two Receptors Binding Surfaces on Basic Fibroblast Growth Factor Required for Mitogenesis. The Journal of Biological Chemistry 269(43):26879-26884.
183Stauber, Deborah J. et al., (2000) Structural interactions of fibroblast growth factor receptor with its ligands. Proc Natl Acad Sci USA 97(1):49-54.
184Stone et al., "Articular Cartilage Paste Grafting to Full-Thickness Articular Cartilage Knee Joint Lesions: A 2- to 12-Year Follow-up", Arthroscopy: The Journal of Arthoscopic and Related Surgery, Mar. 2006, vol. 22, No. 3, pp. 291-299.
185Stone, et al., "One-step American Technique of Articular Cartilage Paste Grafting to Traumatic and Arthritic Defects in the Knee Joint (2-7 Years Follow Up)", downloaded from http://www.stoneclinic.com/onestep.htm, publication date unavailable. Downloaded Apr. 4, 2008.
186Supplementary European Search Report issued on Jun. 28, 2006 in connection with European Patent Application No. 04749924.9.
187Temenoff et al., "Review: Tissue engineering for regeneration of articular cartilage", Biomaterials 21 (2000) pp. 431-440.
188Trzeciak et al., "Evaluation of Cartilage Reconstruction by Means of Autologous Chondrocyte Versus Periosteal Graft Transplantation: An Animal Study", Transplantation Proceedings, vol. 38 (2006), pp. 305-311.
189Tsumaki et al., "Role of CDMP-1 in Skeletal Morphogenesis: Promotion of Mesenchymal Cell Recruitment and Chondrocyte Differentiation", J. Cell Biol., Jan. 1999, vol. 144, No. 1, 161-173.
190U.S. App. No. 12/881,988, filed Sep. 14, 2010.
191U.S. Appl. No. 11/657,042, filed Jan. 24, 2007 titled Two Piece Cancellous Construct for Cartilage Repair.
192U.S. Appl. No. 12/010,984, filed Jan. 31, 2008 titled Cartilage Repair Mixture Containing Allograft Chondroctypes.
193U.S. Appl. No. 12/043,001, filed Mar. 5, 2008 Cancellous Construct with Support Ring for Repair of Osteochondral Defects.
194U.S. Appl. No. 12/079,629, filed Mar. 26, 2008 Titled Cartilage Implant Plug with Fibrin Glue and Method for Implantation.
195U.S. Appl. No. 12/381,072, filed Mar. 5, 2009 entitled "Cancellous Constructs, Cartilage Particles and Combinations of Cancellous Constructs and Cartilage Particles".
196U.S. Appl. No. 12/508,892, filed Jul. 24, 2009 entitled "Cancellous Constructs with Support Ring for Repair of Osteochondral Defects".
197U.S. Appl. No. 12/657,207, filed Jan. 14, 2010.
198U.S. Appl. No. 12/696,366, filed Jan. 29, 2010.
199U.S. Appl. No. 12/924,132, filed Sep. 21, 2010.
200USPTO Communication mailed Oct. 9, 2007 in connection with U.S. Appl. No. 10/438,883.
201Vajo, Zoltan et al., (2000) The Molecular and Genetic Basis of Fibroblast Growth Factor Receptor 3 Disorders: The Achondroplasia Family of Skeletal Dysplasias, Muenke Craniosynostosis, and Crouzon Syndrome with Acanthosis Nigricans. Endocrine Rev. 21(1):23-39.
202Verbruggen et al., "Repair Function in Organ Cultured Human Cartilage. Replacement of Enzymatically Removed Proteoglycans During Longterm Organ Culture", The Journal of Rheumatology, 12:4, 1985, pp. 665-674.
203Vunjak-Novakovic et al., "Bioreactor Cultivation Conditions Modulate the Composition and Mechanical Properties of Tissue-Engineered Cartilage", Journal of Orthopaedic Research, 1999; 17:130-138.
204Wells, James A. (1990) Additivity of mutational effects in proteins. Biochemistry 29(37):8509-8517.
205Written Opinion issued in connection with International Patent Application No. PCT/US2004/010956 on Oct. 28, 2005.
206Written Opinion issued in connection with International Patent Application No. PCT/US2004/010957 on Nov. 1, 2004.
207Written Opinion issued in connection with International Patent Application No. PCT/US2005/008798 on Jun. 19, 2006.
208Written Opinion issued in connection with International Patent Application No. PCT/US2005/036878 on Sep. 21, 2006.
209Written Opinion issued on Apr. 7, 2006 in connection with International Patent Application No. PCT/US2005/030610.
210Yamashita, Tetsuo et al., (2000) Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and Biophysical Research Communications 277 (2):494-498.
211Yayon, Avner et al., (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64(4):841-848.
212Yee, Cindy J. et al., (2000) Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma. Journal of the National Cancer Institute 92(22):1848-1849.
213Zhang, Jiandong et al., (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homolog of interleukin 1 Beta. Proc Natl Acad Sci. USA 88(8):3446-3450.
214Zhu, Hengyi et al., (1995) Glu-96 of basic fibroblast growth factor is essential for high affinity receptor binding. Journal Of Biological Chemistry 270(37):21869-21874.
215Zhu, Hengyi et al., (1997) Analysis of high-affinity binding determinants in the receptor binding epitope of basic fibroblast growth factor. Protein Engineering 10(4):417-421.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US8685432Mar 23, 2009Apr 1, 2014University Of Utah Research FoundationControlled release tissue graft combination biomaterials
Classifications
U.S. Classification424/93.7, 424/548
International ClassificationA61K35/32, A61F2/30, A61F2/02, A61L27/58, A61L27/48, A61L27/56, A61B17/00, A61F2/28, A61F2/00, A61L27/36, A61L27/38, A61F2/38
Cooperative ClassificationA61L2430/06, A61B17/00491, A61F2002/2817, A61L27/3654, A61F2230/0069, A61L27/20, A61F2/30744, A61F2/30756, A61F2/3859, A61L27/3821, A61K35/28, A61F2/3094, A61F2/28, A61F2002/2867, A61L27/3852, A61L27/3683, A61F2310/00383, A61K35/32, A61F2002/30225, A61F2210/0004, A61L27/3834, A61F2002/30764, A61F2310/00365, A61L27/24, A61K38/28, A61L27/3612, A61K38/18, A61L27/58, A61L27/56, A61F2002/30224, A61L27/3817, A61L27/48, A61F2002/30062, A61F2002/30759
European ClassificationA61L27/48, A61L27/58, A61L27/20, A61L27/56, A61F2/30C, A61K35/32, A61L27/24, A61L27/38B6, A61L27/38B8, A61L27/38B14, A61L27/36H, A61L27/36B4, A61L27/38D2D, A61L27/36F2D, A61K38/28, A61K38/18, A61K35/12
Legal Events
DateCodeEventDescription
Nov 23, 2010ASAssignment
Owner name: MUSCULOSKELETAL TRANSPLANT FOUNDATION, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GOMES, KATHERINE A.;SUNWOO, MOON HAE;GERTZMAN, ARTHUR A.;AND OTHERS;SIGNING DATES FROM 20040224 TO 20040317;REEL/FRAME:025399/0509